

Academic Program Regulations – 2017

Based on PCI Notification in the Gazette of India, No 362, dated 11 December, 2014

<u>Program Title</u>: MPharm (Master of Pharmacy) CBCS (Choice Based Credit System)

Specialization: Pharmacology

Manipal College of Pharmaceutical Sciences Manipal Academy of Higher Education Manipal-576 104, Karnataka, India



Academic Program Regulations – 2017 : MPharm, CBCS – Approval

The Master of Pharmacy (MPharm) program, CBCS of Manipal Academy of Higher Education being offered at Manipal College of Pharmaceutical Sciences under the title "Academic Program Regulations – 2017: MPharm, CBCS" has been duly approved by the Academic Council of Manipal Academy of Higher Education.



REGISTRAR



manipal.edu, Madhav Nagar, Manipal 576104, Karnataka, India dir. 91 820 2571201 fax. 91 820 2570062 www.manipal.edu

Table of Contents

S. No.	Content	Page No.
	Chapter I: Regulations	01-25
1	Short title and commencement	01
2	Minimum qualification for admission	01
3	Duration of the program	01
4	Medium of instruction and examinations	01
5	Working days in each semester	01
6	Attendance and progress	02
7	Program/Course credit structure	02
8	Academic work	03
9	Course work of study	03
10	Program committee	17
11	Examinations/Assessments	17
12	Pass and award of performance grades	20
13	Make-up/Supplementary examination	23
14	Improvement of internal assessment	23
15	Promotion to the next higher class	24
16	Declaration of class	24
17	Research project work	24
18	Award of degree	25
19	Duration for completion of the program	25
20	Revaluation of answer papers	25
21	Re-admission after break of study	25
	Chapter II :	27-34
22	OBE Framework	29
23	Vision	30
24	Mission	30
25	Quality Policy	30
26	Program Education Objective	31
27	Program Outcome	33
	Chapter III: Syllabus	35-95
28	Sem 1-1 PQA-MPL101T	39
29	Sem 1-2 PHA-MPL102T	42
30	Sem 1-3 PHA-MPL103T	45
31	Sem 1-4 PHA-MPL104T	48
32	Sem 1-5 PHA-MPL105P	51
33	Sem 1-6 PHA-MPL106S	54
34	Sem 2-1 PHA-MPL201T	55
35	Sem 2-2 PHA-MPL202T	58
36	Sem 2-3 PHA-MPL203T	61
37	Sem 2-4 PHA-MPL204T	64
38	Sem 2-5 PHA-MPL205P	67
37	Sem 2-6 PHA-MPL206S	70
38	Sem 3-1 PHA-MRM301T	71
39	Sem 3-2 MJC302P	73
40	Sem 4 Choice Based Electives	74

REGD. NO. D. L.-33004/99

रजिस्ट्री सं० डी॰ एल॰-33004/99



EXTRAORDINARY भाग III—खण्ड 4 PART III—Section 4 प्राधिकार से प्रकाशित

PUBLISHED BY AUTHORITY

सं. 362] नई दिल्ली, बृहस्पतिवार, दिसम्बर 11, 2014/अंग्रहायण 20, 1936 No. 362] NEW DELHI, THURSDAY, DECEMBER 11, 2014/AGRAHAYANA 20, 1936

PHARMACY COUNCIL OF INDIA NOTIFICATION

New Delhi, the 10th December, 2014

The Master of Pharmacy (M.Pharm) Course Regulations, 2014

No. 14-136/ 2014-PCL—In exercise of the powers conferred by Sections 10 and 18 of the Pharmacy Act, 1948 (8 of 1948), the Pharmacy Council of India, with the approval of the Central Government hereby makes the following regulations; namely-

CHAPTER I: REGULATIONS

1. Short title and commencement

These regulations shall be called as "Master of Pharmacy (MPharm) Degree Program-Regulations -Choice Based Credit System (CBCS). The program regulations are based on the PCI notification in the Gazette of India, No. 362, dated 11 December 2014.

They shall come into effect from the academic year 2017-18. The regulations framed are subject to modifications from time to time by the authorities of the Manipal Academy of Higher Education.

2. Minimum qualification for admission

A pass in the following examinations

- a) BPharm degree examination of an Indian university established by law in India from an institution approved by Pharmacy Council of India and has scored not less than 55% of the maximum marks (aggregate of 4 years of BPharm).
- b) Every student, selected for admission to postgraduate pharmacy program in any PCI approved institution should have obtained registration with the State Pharmacy Council or should obtain the same within one month from the date of his/her admission, failing which the admission of the candidate shall be cancelled.
- c) Any foreign pharmacy degree approved by the Pharmacy Council of India.

Note: It is mandatory to submit a migration certificate obtained from the respective university where the candidate had passed his/her qualifying degree (BPharm)

3. Duration of the program

The program of study for MPharm shall extend over a period of four semesters (two academic years). The curricula and syllabi for the program shall be prescribed from time to time by Manipal Academy of Higher Education based on the inputs from Pharmacy Council of India, New Delhi.

4. Medium of instruction and examination

Medium of instruction and examination shall be in English.

5. Working days in each semester

Each semester shall consist of not less than 100 working days. The odd semesters shall be conducted from the month of July/August to November/December and the even semesters shall be conducted for the month of December/January to May/June in an academic year.

6. Attendance and progress

A candidate is required to put in at least 80% attendance in individual courses considering the theory and practical separately. The candidate shall complete the prescribed course satisfactorily to be eligible to appear for the respective examinations.

7. Program/Course credit structure

As per the philosophy of Credit Based Semester System, certain quantum of academic work viz. theory classes, practical classes, seminars etc., are measured in terms of credits. On satisfactory completion of the courses, a candidate earns credits. The amount of credit associated with a course is dependent upon the number of hours of instruction per week in that course. Similarly, the credit associated with any of the other academic, co-curricular activities is dependent upon the quantum of work expected to be put in for each of these activities per week/per activity.

7.1. Credit assignment

7.1.1. Theory and laboratory courses

Courses are broadly classified as Theory and Practical. Theory courses consist of Lecture (L) and tutorial (T). Practical (P) courses consist of hours spent in the laboratory. Credits (C) for a course are dependent on the number of hours of instruction per week in that course, and is obtained by using a multiplier of one (1) for lecture/tutorial and a multiplier of half ($\frac{1}{2}$) for practical (laboratory) hours. Thus, for example, a theory course, having four lectures per week throughout the semester carries a credit of 4. Similarly, a practical having four laboratory hours per week throughout the semester carries a credit of 2. The contact hours of seminars, and research work and journal club shall be treated as that of practical courses for the purpose of calculating credits, i.e., the contact hours shall be multiplied by $\frac{1}{2}$.

7.2. Minimum credit requirements

The minimum credit points required for the award of MPharm degree is 95. However, based on the credit points earned by the students under the heads of co-curricular activities and choice based inter/multidisciplinary courses, a student shall earn a maximum of 100 credit points. These credits are divided into theory courses, practical, seminars, research work, journal club and co-curricular activities over the duration of four semesters. The credits are distributed semester-wise as shown in Table 14. Courses generally progress in sequence, building competencies and their positioning indicate certain academic maturity on the part of the learners. Learners are expected to follow the semester-wise schedule of courses given in the syllabus.

8. Academic work

A regular record of attendance both in theory, practical, seminar, assignment, journal club, discussion with the supervisor, research work presentation and dissertation shall be maintained by the department/teaching staff of the respective courses.

9. Course work of study

Table 1.	Table 1. List of MPharm specializations and their codes						
S. No.	Specialization	Code					
1	Pharmaceutics	MPH					
2	Industrial Pharmacy	MIP					
3	Pharmaceutical Chemistry	MPC					
4	Pharmaceutical Analysis	MPA					
5	Pharmaceutical Quality Assurance	MQA					
6	Pharmaceutical Regulatory Affairs	MRA					
7	Pharmaceutical Biotechnology	MPB					
8	Pharmacy Practice	MPP					
9	Pharmacology	MPL					
10	Pharmacognosy	MPG					

The specializations in MPharm program are given in Table 1.

The course work of MPharm specializations shall include semester wise theory and practical as given in Table 2 to 13. The number of hours to be devoted to each theory lectures (L), tutorials (T) and practical (P) course in any semester shall not be less than that shown in Table 2 to 13.

Table 2.	Course work of MPharm – F	harmace	eutics (MF	PH) special	ization	
Course	Course Title	Cre	Credit hours/week			Marks
Code		Lecture	Tutorial	Practical	Points	
		(L)	(T)	(P)		
Semester I						
PQA-MPH101T	Modern Pharmaceutical	4			4	100
	Analytical Techniques					
PCE-MPH102T	Drug Delivery Systems	4	1		5	100
PCE-MPH103T	Modern Pharmaceutics	4	1		5	100
PRM-MPH104T	Regulatory Affairs	4	1		5	100
PCE-MPH105P	Pharmaceutics Practical I			12	6	150
PCE-MPH106S	Seminar*			2	1	100
	Total	16	3	14	26	650
Semester II						
PCE-MPH201T	Molecular Pharmaceutics	4	1		5	100
	(Nano Tech and Targeted					
	DDS)					
PCE-MPH202T	Advanced Biopharmaceutics	4	1		5	100
	and Pharmacokinetics					
PCE-MPH203T	Computer Aided Drug	4	1		5	100
	Delivery Systems					
PCE-MPH204T	Cosmetic and	4	1		5	100
	Cosmeceuticals					
PCE-MPH205P	Pharmaceutics Practical II			12	6	150
PCE-MPH206S	Seminar*			2	1	100
	Total	16	4	14	27	650
* No end-semester	examination. Only continuous	mode				

Table 3. (Course work of MPharm –Ind	ustrial Pl	narmacy (MIP) speci	ialization	l
Course	Course Title	Cre	edit hours	/week	Credit	Marks
Code		Lecture	Tutorial	Practical	Points	
		(L)	(T)	(P)		
Semester I	·					
PQA-MIP101T	Modern Pharmaceutical	4			4	100
	Analytical Techniques					
DCE MID102T	Pharmaceutical Formulation	4	1		5	100
PCE-MIP1021	Development					
PCF MID103T	Novel Drug Delivery	4	1		5	100
	Systems					
PRM-MIP104T	Intellectual Property Rights	4	1		5	100
DCF MID105D	Industrial Pharmacy			12	6	150
	Practical I					
PCE-MIP106S	Seminar*			2	1	100
	Total	16	3	14	26	650
Semester II						
PCF-MIP201T	Advanced Biopharmaceutics	4	1		5	100
1 CE MII 2011	and Pharmacokinetics					
PCE-MIP202T	Scale-up and Technology	4	1		5	100
1 CE MII 2021	Transfer					
PCE-MIP203T	Pharmaceutical Production	4	1		5	100
	Technology					
PRM-MIP204T	Entrepreneurship	4	1		5	100
	Management					
PCE-MIP205P	Industrial Pharmacy			12	6	150
	Practical II					
PCE-MIP206S	Seminar*			2	1	100
	Total	16	4	14	27	650
* No end-semester	examination. Only continuous	mode.				

Table 4. Cour	Table 4. Course work of MPharm – Pharmaceutical Chemistry (MPC) specialization					tion
Course	Course Title	Cre	dit hours	/week	Credit	Marks
Code		Lecture	Tutorial	Practical	Points	
		(L)	(T)	(P)		
Semester I						
PQA-MPC101T	Modern Pharmaceutical	4			4	100
	Analytical Techniques					
PCH_MPC102T	Advanced Organic	4	1		5	100
1 CH-IVII C1021	Chemistry I					
PCH_MPC103T	Advanced Medicinal	4	1		5	100
1 CH-WH C1051	Chemistry					
PCH-MPC104T	Chemistry of Natural	4	1		5	100
	Products					
PCH-MPC105P	Pharmaceutical Chemistry			12	6	150
1 CH WH C1051	Practical I					
PCH-MPC106S	Seminar*			2	1	100
	Total	16	3	14	26	650
Semester II	1	T	r	1	r	r
PCH-MPC201T	Advanced Spectral Analysis	4	1		5	100
PCH-MPC202T	Advanced Organic	4	1		5	100
1 CH MH C2021	Chemistry II					
PCH-MPC203T	Computer Aided Drug	4	1		5	100
	Design					
PCH-MPC204T	Pharmaceutical Process	4	1		5	100
	Chemistry					
PCH-MPC205P	Pharmaceutical Chemistry			12	6	150
	Practical II					
PCH-MPC206S	Seminar*			2	1	100
	Total	16	4	14	27	650
* No end-semester	examination. Only continuous	node.				

Table 5. Cou	Table 5. Course work of MPharm – Pharmaceutical Analysis (MPA) specialization					
Course	Course Title	Cre	edit hours	/week	Credit	Marks
Code		Lecture	Tutorial	Practical	Points	
		(L)	(T)	(P)		
Semester I	•					
PQA-MPA101T	Modern Pharmaceutical	4			4	100
	Analytical Techniques					
PCH-MPA102T	Advanced Pharmaceutical Analysis	4	1		5	100
PCH-MPA103T	Pharmaceutical Validation	4	1		5	100
PCH-MPA104T	Food Analysis	4	1		5	100
DCH MDA 105D	Pharmaceutical Analysis			12	6	150
rcn-wrAl03r	Practical I					
PCH-MPA106S	Seminar*			2	1	100
	Total	16	3	14	26	650
Semester II						
PCH-MPA201T	Advanced Instrumental Analysis	4	1		5	100
PCH-MPA202T	Modern Bioanalytical Techniques	4	1		5	100
PCH-MPA203T	Quality Control and Quality Assurance	4	1		5	100
PCH-MPA204T	Herbal and Cosmetic Analysis	4	1		5	100
PCH-MPA205P	Pharmaceutical Analysis Practical II			12	6	150
PCH-MPA206S	Seminar*			2	1	100
	Total	16	4	14	27	650
* No end-semester	examination. Only continuous	mode.				

Table 6. Course work of MPharm – Pharmaceutical Quality Assurance (MQA)						
Course	Course Title	Lation	dit hours	/wook	Credit	Morke
Code	Course Thie			week	Points	IVIALKS
Coue		Lecture	Tutorial	Practical	TOIL	
		(L)	(T)	(P)		
Semester I		1	1	I	1	
PQA-MQA101T	Modern Pharmaceutical Analytical Techniques	4			4	100
PQA-MQA102T	Quality Management Systems	4	1		5	100
PQA-MQA103T	Quality Control and Quality Assurance	4	1		5	100
PQA-MQA104T	Product Development and Technology Transfer	4	1		5	100
PQA-MQA105P	Pharmaceutical Quality Assurance Practical I			12	6	150
PQA-MQA106S	Seminar*			2	1	100
	Total	16	3	14	26	650
Semester II						
PQA-MQA201T	Hazards and Safety Management	4	1		5	100
PQA-MQA202T	Pharmaceutical Validation	4	1		5	100
PQA-MQA203T	Audits and Regulatory Compliance	4	1		5	100
PQA-MQA204T	Pharmaceutical Manufacturing Technology	4	1		5	100
PQA-MQA205P	Pharmaceutical Quality Assurance Practical II			12	6	150
PQA-MQA206S	Seminar*			2	1	100
	Total	16	4	14	27	650
* No end-semester	examination. Only continuous	mode.				

Table 7. Course work of MPharm – Pharmaceutical Regulatory Affairs (MRA) specialization						
Course	Course Title	Cre	dit hours	/week	Credit	Marks
Code		Lecture (L)	Tutorial (T)	Practical (P)	Points	
Semester I						
PRM-MRA101T	Good Regulatory Practices	4			4	100
PRM-MRA102T	Documentation and Regulatory Writing	4	1		5	100
PRM-MRA103T	Clinical Research Regulations	4	1		5	100
PRM-MRA104T	Regulations and Legislation for Drugs & Cosmetics, Medical Devices, Biologicals & Herbals and Food & Nutraceuticals in India and Intellectual Property Rights	4	1		5	100
PRM-MRA105P	Regulatory Affairs Practical I			12	6	150
PRM-MRA106S	Seminar*			2	1	100
	Total	16	3	14	26	650
Semester II						
PRM-MRA201T	Regulatory Aspects of Drugs and Cosmetics	4	1		5	100
PRM-MRA202T	Regulatory Aspects of Herbal and Biologicals	4	1		5	100
PRM-MRA203T	Regulatory Aspects of Medical Devices	4	1		5	100
PRM-MRA204T	Regulatory Aspects of Food and Nutraceuticals	4	1		5	100
PRM-MRA205P	Regulatory Affairs Practical II			12	6	150
PRM-MRA206S	Seminar*			2	1	100
	Total	16	4	14	27	650
* No end-semester	examination. Only continuous	mode.				

Table 8. Course	e work of MPharm – Pharmac	eutical B	Biotechnol	ogy (MPB)	specializ	zation
Course	Course Title	Cre	edit hours	/week	Credit	Marks
Code		Lecture	Tutorial	Practical	Points	
		(L)	(T)	(P)		
Semester I						•
PQA-MPB101T	Modern Pharmaceutical	4			4	100
	Analytical Techniques					
DRT MDR102T	Microbial and Cellular	4	1		5	100
FD1-WIFD1021	Biology					
DRT MDR103T	Bioprocess Engineering and	4	1		5	100
FDI-IVIFD1031	Technology					
DRT MDR104T	Advanced Pharmaceutical	4	1		5	100
1 D1-WII D1041	Biotechnology					
DRT MDR105D	Pharmaceutical			12	6	150
FDI-WIFD105F	Biotechnology Practical I					
PBT-MPB106S	Seminar*			2	1	100
	Total	16	3	14	26	650
Semester II						
	Proteins and Protein	4	1		5	100
	Formulations					
PBT-MPB202T	Immunotechnology	4	1		5	100
	Bioinformatics and	4	1		5	100
PBT-MPB203T	Computational					
	Biotechnology					
DRT MDR204T	Biological Evaluation of	4	1		5	100
FD1-WIFD2041	Drug Therapy					
DRT MDR205D	Pharmaceutical			12	6	150
FDI-IMFD203F	Biotechnology Practical II					
PBT-MPB206S	Seminar*			2	1	100
	Total	16	4	14	27	650
* No end-semester	examination. Only continuous	mode.				

Table 9.	Course work of MPharm – Ph	armacy F	Practice (N	MPP) speci	alization	
Course	Course Title	Cre	Credit hours/week			Marks
Code		Lecture	Tutorial	Practical	Points	
		(L)	(T)	(P)		
Semester I						
PPR-MPP101T	Clinical Pharmacy Practice	4			4	100
PPR-MPP102T	Pharmacotherapeutics I	4	1		5	100
DDD MDD103T	Hospital and Community	4	1		5	100
	Pharmacy					
PPR-MPP104T	Clinical Research	4	1		5	100
PPR-MPP105P	Pharmacy Practice Practical I			12	6	150
PPR-MPP106S	Seminar*			2	1	100
	Total	16	3	14	26	650
Semester II						
DDD MDD201T	Principles of Quality Use of	4	1		5	100
FFK-WIFF 2011	Medicines					
PPR-MPP202T	Pharmacotherapeutics II	4	1		5	100
	Clinical Pharmacokinetics	4	1		5	100
PPR-MPP203T	and Therapeutic Drug					
	Monitoring					
DDD MDD204T	Pharmacoepidemiology and	4	1		5	100
FFK-WIFF2041	Pharmacoeconomics					
PPR-MPP205P	Pharmacy Practice Practical II			12	6	150
PPR-MPP206S	Seminar*			2	1	100
	Total	16	4	14	27	650
* No end-semester	examination. Only continuous	mode.				

Table 10	. Course work of MPharm –	Pharmac	ology (M	PL) special	ization	
Course	Course Title	Cre	edit hours	/week	Credit	Marks
Code		Lecture	Tutorial	Practical	Points	
		(L)	(T)	(P)		
Semester I						
PQA-MPL101T	Modern Pharmaceutical	4			4	100
	Analytical Techniques	4	1		~	100
PHA-MPL102T	Advanced Pharmacology I	4	1		5	100
PHA-MPL103T	PharmacologicalandToxicologicalScreeningMethods I	4	1		5	100
PHA-MPL104T	Cellular and Molecular Pharmacology	4	1		5	100
PHA-MPL105P	Pharmacology Practical I			12	6	150
PHA-MPL106S	Seminar*			2	1	100
	Total	16	3	14	26	650
Semester II						
PHA-MPL201T	Advanced Pharmacology II	4	1		5	100
PHA-MPL202T	PharmacologicalandToxicologicalScreeningMethods IIScreening	4	1		5	100
PHA-MPL203T	Principles of Drug Discovery	4	1		5	100
PHA-MPL204T	Clinical Research and Pharmacovigilance	4	1		5	100
PHA-MPL205P	Pharmacology Practical II			12	6	150
PHA-MPL206S	Seminar*			2	1	100
	Total	16	4	14	27	650
* No end-semester	examination. Only continuous 1	mode.				

Table 11.	Course work of MPharm – P	harmaco	ognosy (M	PG) specia	lization	
Course	Course Title	Cre	dit hours	Credit	Marks	
Code		Lecture	Tutorial	Practical	Points	
		(L)	(T)	(P)		
Semester I						
PQA-MPG101T	Modern Pharmaceutical	4			4	100
	Analytical Techniques					
PCO-MPG102T	Advanced Pharmacognosy I	4	1		5	100
PCO-MPG103T	Phytochemistry	4	1		5	100
PCO MPC104T	Industrial Pharmacognostical	4	1		5	100
PCO-MPG1041	Technology					
PCO-MPG105P	Pharmacognosy Practical I			12	6	150
PCO-MPG106S	Seminar*			2	1	100
	Total	16	3	14	26	650
Semester II						
PCO MDC201T	Medicinal Plant	4	1		5	100
FCO-IVIF 02011	Biotechnology					
PCO-MPG202T	Advanced Pharmacognosy II	4	1		5	100
PCO-MPG203T	Indian Systems of Medicine	4	1		5	100
PCO-MPG204T	Herbal Cosmetics	4	1		5	100
PCO-MPG205P	Pharmacognosy Practical II			12	6	150
PCO-MPG206S	Seminar*			2	1	100
	Total	16	4	14	27	650
* No end-semester	examination. Only continuous	mode.				

Table 13. Course work for MPharm III and IV semesters(Common for all specializations)						
Course	Course Title	Credit hours/week Credit Mar				Marks
Code		Lecture Tutorial Practical		Points		
		(L)	(T)	(P)		
PHA-MRM301T	Research Methodology and	4			4	100
	Biostatistics*					
MJC302P	Journal Club*			2	1	100
MRW401P	Research Work			70	35	600
Total 4 72 40 800						
* No end-semester	* No end-semester examination. Only continuous mode					

Table 14. Semester wise course work credits distribution					
Semester	Credit Points				
Ι	26				
П	27				
III and IV	40				
Total course work credits	93				
Co-curricular activities (Attending conference, scientific presentations, other scholarly activities and choice based inter/multidisciplinary courses)	Minimum=02* Maximum=07*				
Total credit points	Minimum=95 Maximum=100				

*Credit points for co-curricular activities (Table 15A) and choice based inter/multidisciplinary courses (Table 15B).

Table 15A. Guidelines for awarding credit points for co-curricular activities				
Name of the Activity	Maximum Credit Points Eligible/ Activity			
Participation in National level seminar/Conference/Workshop/Symposium/Training programs (related to the specialization of the student)	01			
Participation in International level seminar/Conference/Workshop/Symposium/Training programs (related to the specialization of the student)	02			
Academic award/ Research award from State level/National agencies	01			
Academic award/Research award from International agencies	02			
Research/ Review publication in National journals (Indexed in Scopus/Web of Science)	01			
Research/ Review publication in International journals (Indexed in Scopus/Web of Science)	02			

Note: International conference: Held outside India

International journal: The editorial board outside India

*The credit points assigned for extracurricular and or co-curricular activities shall be given by the principal of the college and the same shall be submitted to the university. The criteria to acquire this credit point shall be defined by the college from time to time.

Table 15B. List of choice based inter/multidisciplinary courses								
Course	Course Title	Credits	Department/Institution offering the					
Code			Course					
Interdisciplinary courses								
PCE-001E	Generic Drug Development	1	Pharmaceutics, MCOPS					
PCE-002E	Pharmaceutical Dissolution Technology	1	Pharmaceutics, MCOPS					
PCE-003E	Particulate Drug Delivery Systems	1	Pharmaceutics, MCOPS					
PCE-004E	3D Printing in Pharmaceutical Manufacturing	1	Pharmaceutics, MCOPS					
PCH-001E	Preparative Separation Techniques	1	Pharmaceutical Chemistry, MCOPS					
PCH-002E	Molecular Modeling and Drug Design	1	Pharmaceutical Chemistry, MCOPS					
PCH-003E	Hyphenated Techniques	1	Pharmaceutical Chemistry, MCOPS					
PCH-004E	Chemicals - Environment, Health and Safety	1	Pharmaceutical Chemistry, MCOPS					
PQA-001E	Theory and Practice of Analytical and Bioanalytical Method Development and Validation	1	Pharmaceutical Quality Assurance, MCOPS					
PQA-002E	Good Documentation Practices and e- Documentation Practices in Pharmaceutical Industry	1	Pharmaceutical Quality Assurance, MCOPS					
PQA-003E	Trouble Shooting in High Performance Liquid Chromatography	1	Pharmaceutical Quality Assurance, MCOPS					
PQA-004E	Professional Development	1	Pharmaceutical Quality Assurance, MCOPS					

PQA-005E	Stability Testing of Drugs and Biologicals	1	Pharmaceutical Quality Assurance, MCOPS	
PQA-006E	USFDA Drug Regulatory Affairs	1	Pharmaceutical Quality Assurance, MCOPS	
PQA-007E	Rest of the World Drug Regulations	1	Pharmaceutical Quality Assurance, MCOPS	
PQA-008E	Evaluation of Medical Devices	1	Pharmaceutical Quality Assurance, MCOPS	
PBT-001E	Clean Room Concepts	1	Pharmaceutical Biotechnology, MCOPS	
PBT-002E	Biosimilars	1	Pharmaceutical Biotechnology, MCOPS	
PBT-003E	Principles of Gene Cloning	1	Pharmaceutical Biotechnology, MCOPS	
PBT-004E	Tissue Engineering	1	Pharmaceutical Biotechnology, MCOPS	
PPR-001E	Retail Pharmacy Practice	- 1	Pharmacy Practice MCOPS	
PPR-002E	Fundamentals of Medical Writing	1	Pharmacy Practice, MCOPS	
PPR-003E	Systematic Review and Meta- Analysis	1	Pharmacy Practice, MCOPS	
PPR-004E	Pharmacokinetics Data Analysis (Employing WinNonlin)	1	Pharmacy Practice, MCOPS	
PHA-001E	Cancer Biology	1	Pharmacology, MCOPS	
РНА-002Е	Screening Methods for Drug Development	1	Pharmacology, MCOPS	
РНА-003Е	Free Radical Biology and Medicine	1	Pharmacology, MCOPS	
PHA-004E	Regulatory Toxicology in Drug Discovery and Development	1	Pharmacology, MCOPS	
PCO-001E	Nutraceuticals	1	Pharmacognosy, MCOPS	
PCO-002E	Extraction, Separation and	1	Pharmacognosy, MCOPS	
	Purification of			
	Phytoconstituents	1		
PCO-003E	Nanophytopharmaceuticals	1	Pharmacognosy, MCOPS	
PCO-004E	Herbal Monographs	1	Pharmacognosy, MCOPS	
PRM-001E	Retail Business Management	1	Pharmaceutical Regulatory Affairs & Management, MCOPS	
PRM-002E	Intellectual Property Management	1	Pharmaceutical Regulatory Affairs & Management, MCOPS	
PRM -003E	General Management Principles	1	Pharmaceutical Regulatory Affairs & Management, MCOPS	
PRM -004E	Entrepreneurship Development	1	Pharmaceutical Regulatory Affairs & Management MCOPS	
Multidisciplin	ary courses		Wanagement, Webi 5	
MU-001E	Certificate Course in	3	School of Life Sciences, MU	
	Bioinformatics	-		
MU-002E	Project Management	4	Department of Humanities and Social Science, MIT	
MU-003E	Certificate Course in Bioethics	2/4	Centre for Bioethics, MU	
MU-004E	Academic Research and Writing	3	Manipal Centre for Philosophy and Humanities, MU	
MU-005E	Certificate Course in Biosecurity	5	Dept. of Public Health, MU	
CR-001E	Any one of the Online courses	1 and above	Coursera	

10. Program committee

1. The MPharm program shall have a program committee constituted by the Head of the Institution in consultation with all the Heads of the Departments.

2. The composition of the program committee shall be as follows: A teacher at the cadre of professor shall be the Chairperson; One teacher from each MPharm specialization and four student representatives (two from each academic year), nominated by the Head of the Institution.

3. Duties of the program committee:

- i. Periodically reviewing the progress of the classes.
- ii. Discussing the problems concerning curriculum, syllabus and the conduct of classes.
- iii. Discussing with the course teachers on the nature and scope of assessment for the course and the same shall be announced to the students at the beginning of respective semesters.
- iv. Communicating its recommendation to the Head of the Institution on academic matters.
- v. The program committee shall meet at least twice in a semester, preferably at the end of each sessional exam and before the end semester exam.

11. Examinations/Assessments

The schemes for internal assessment and end-semester examinations are given in Table 16.

Table 16. Schemes for internal assessments and end semester examinations							
	Internal Assessment			End-Semest			
Course	Contin	tin Sessional Exams					Total
	uous Mode	Marks	Duration	Total	Marks	Duration	Marks
	Widde		Semester I	and II			
Theory	10	15	1 hr each	25	75	3 hrs	100
Practical	20	30	6 hrs	50	100	6 hrs	150
Seminar				100			100
		S	emester III	and IV			
PHA-MRM301T Research Methodology and Biostatistics*	20	40+40	2 hrs each	100			100
MJC302P Journal Club*				100			100
MRW401P Research Work		100+100	1 hr each	200	400		600
* No end-semester examination. Only continuous mode							

11.1. Internal assessment: Continuous mode

The marks allocated for continuous mode of internal assessment of theory courses shall be awarded based on the students' performance in the assignments/surprise tests, etc., while in the lab course it is based on the practical record, regular viva-voce etc.

11.1.1. Sessional exams

Two sessional exams for each theory course and one sessional examination for a practical course shall be conducted as per the schedule fixed by the college. The schemes of question papers for theory and practical sessional examinations are given below. The average marks of two sessional examinations of theory courses shall be computed for internal assessment of 15 marks as given in Table 16.

Question paper pattern – MPharm Theory sessional examinations						
Manipal College of Pharmaceutical Sciences						
Manipal Aca	demy of Higher Education, Man	ipal				
MPharm Theory Sessional Examinations, Month and Year						
<u>C</u>	<u>ourse Code. Course Title</u>					
Date: dd-mm-yyyy	Duration: 2 hrs	Max. Marks: 45				
Instru	ctions: Answer ALL questions					
Long Essays (2x 10 marks) = 20 ma	arks					
1. Question						
2. Question						
Short Essays $(4 \times 5 \text{ marks}) = 20 \text{ marks}$	rks					
3. Question						
4. Question						
5. Question						
6. Question						
7. Short answers (1 mark \times 5 = 5 m	arks)					
7A.						
7B.						
7C.						
7D.						
7E.	7E.					

Question paper pattern – MPharm practical sessional examinations						
Manipal College of Pharmaceutical Sciences						
Manipal Academy of Higher Education, Manipal						
MPharm Practical Sessional Examinations, Month and Year						
Course Code. Course Title						
Date: dd-mm-yyyy	Duration: 6 hrs	Max. Marks: 60				
Instruction	ons: Answer ALL questions.					
1. Synopsis (10 marks)						
2. Major Experiment (25 marks)	2. Major Experiment (25 marks)					
3. Minor Experiment (15 marks)						

4. Viva-Voce (10 marks)

Pharm seminar evaluation scheme									
PRESENTATION (50 Marks)				Marks awarded for each criteria					
		Criteria			Te	acher 1		Teacher 2	
1	Preparedness	(10 marks)							
2	Response to q	uestions (10 mar	ks)						
3	Audio-visual	aids (10 marks)							
4	Clarity of pres	sentation (10 mar	·ks)						
5	Breadth and d	epth of material	presented (10 ma	arks)					
	Marks awarded								
Average marks awarded for presentation out of $50 (A) =$									
WR	WRITE UP (50 Marks)								
Mai	rks awarded for	each criterion							
(c rele	Content optimum and evant to topic) (10 marks)	Recent information or out of date (10 marks)	tOrganizationDiagram, illustrationsOr (10ion(sequent and methodical)illustrations & references(10datemethodical)& references(10(ss)(10 marks)(10 marks)(10		Originality (10 marks) (10 marks)		Marks awarded for write up out of 50 (B)		
Remarks if any:									
Seminar marks awarded out of 100 = (A+B) =									

11.2 End-semester examination

End-semester examinations are conducted for eligible students twice at the end of the semester, namely, the main examination for regular students and the make-up/supplementary examinations for the failed students only before the commencement of the next semester (Table 17). In case a failed student could not clear the course in the make-up/supplementary examination, the student would have his next examination along with the regular students only in the main examination.

Table 17. Tentative schedule of end-semester examinations						
Semester	Main Examination	Make-up/Supplementary Exams				
I and III	November/December	December/January				
II and IV	May/June	July/August				
Question	paper pattern – MPharm theory	y end-semester examinations				
	Manipal Academy of Higher Ed	ducation, Manipal				
MPhar	m Theory End-Semester Exami	nations, Month and Year				
Course Code. Course Title						
Date: dd-mm-yyyy	Duration: 3	hrs Max. Marks: 75				
	Instructions: Answer AL	L questions.				
 Answer the following (10 marks × 5 = 50 marks) 1. Question 2. Question 3. Question 4. Question 5. Question 5. Question Answer the following with specific answers (5 marks × 5 = 25 marks) 6A. 6B. 6C. 						
6D. 6F						
UL.						

Question paper pattern – MPharm practical end-semester examinations							
MPharm Practical End	MPharm Practical End-Semester Examinations, Month and Year						
Manipal Academy of Higher Education, Manipal							
Course Code. Course Title							
Date: dd-mm-yyyy	Duration: 6 hrs	Max. Marks					
100							
Instructi	ons: Answer ALL questions.						
1. Synopsis (15 marks)	1. Synopsis (15 marks)						
2. Major Experiment (45 marks)							
3. Minor Experiment (25 marks)							
4. Viva-Voce (15 marks)							

12. Pass and award of performance grades

12.1: Minimum for a pass in a course

A student should obtain a minimum of 35% marks in the end-semester exam of each course. A student shall be declared PASS if, the candidate secures E-grade separately in each course, in a 10-

Point-Relative-Letter Grading-Scheme. Accordingly, no candidate shall be declared to have passed in any course unless he/she obtains a grade not less than E-grade.

12.2 Award of performance grades

The marks obtained in the end semester and internal assessments in a course are added together and a 10-Point-Relative-Letter Grading Scheme is used to allot an appropriate letter grade to the student's performance in that course.

12.3 The 10-Point-Relative-Letter-Grading- Scheme

The letter grades and grade points that are used to assess the students' performance in a course are given in the Table 18

Table 18. 10-Point-Relative-Letter Grading-Scheme						
Letter Grade	Grade Point	Performance				
A+	10	Outstanding				
А	9	Excellent				
В	8	Good				
С	7	Fair				
D	6	Average				
Е	5	Pass				
F/I/DT/ab	0	Fail				

F: Fails, I: Incomplete, DT: Detained, ab: Absent

Note the following:

- 1. Internal assessment marks and end-semester examination marks put together are taken into account for the 10-Point-Relative-Letter Grading-Scheme in each course separately. However, the scheme is applied to a student who scores minimum 35% marks in the end-semester examination of each course.
- 2. Appropriate letter grades, from E to A+, are awarded, in each theory and lab courses, to only such candidate who has passed the course in first attempt. However, grades E to C are only awarded to a student who makes multiple attempts to pass a course; except in case of I-grade.
- 3. A candidate who is eligible and registers for the end-semester examination but fails to appear in the end-semester examination or fails in the course gets a grade 'ab', indicating failure.
- 4. A student who is eligible and registers for the end-semester examination but fails to appear in the end-semester examination due to valid reasons will get a grade 'I', indicating incomplete. However, it needs prior approval of the HOI and the Registrar Evaluation, Manipal Academy of Higher Education.
- 5. The grade DT is given to a candidate who fails to put in the minimum required attendance for appearing the end-semester examination for a course.
- 6. A student who earns a grade 'E' or above in a course is declared to have successfully completed the course and earns the credits assigned to that particular course. A course successfully completed cannot be repeated for the purpose of improving the grade.
- 7. Final evaluation of the performance of a student in each course (theory and lab separately) will be carried out on a 10-Point-Letter Grading-Scheme corresponding to the marks obtained in that course. Eventually each letter grade of the course is converted into a specific grade point associated with the letter grade as given in the table above.

12.4 The Semester Grade Point Average (SGPA)

<u>Note</u>: For the calculation of SGPA and CGPA, the credits assigned for course work are only taken for account.

The performance of a student in a semester is indicated by a number called 'Semester Grade Point Average' (SGPA). The SGPA is the weighted average of the grade points obtained in all the courses by the student during the semester. For example, if a student takes four courses (Theory/Practical) in a semester with credits C1, C2, C3 and C4 and the student's grade points in these courses are G1, G2, G3 and G4, respectively, and then students' SGPA is equal to:

$$SGPA = \frac{C1G1 + C2G2 + C3G3 + C4G4}{C1 + C2 + C3 + C4}$$

The SGPA is calculated to two decimal points. It should be noted that, the SGPA for any semester shall take into consideration the F and ab-grade awarded in that semester. For example if a learner has F or ab-grade in course 4, the SGPA shall then be computed as:

$$SGPA = \frac{C1G1 + C2G2 + C3G3 + C4 * ZERO}{C1 + C2 + C3 + C4}$$

12.5. Cumulative Grade Point Average (CGPA)

The CGPA is calculated with the SGPA of all the IV semesters to two decimal points and is indicated in the final grade report card/final transcript showing the grades of all IV semesters and their courses. The CGPA shall reflect the failed status in case of F grade(s), till the course(s) is/are passed. When the course(s) is/are passed by obtaining a pass grade on subsequent examination(s) the CGPA shall only reflect the new grade and not the fail grades earned earlier. The CGPA is calculated as:

$$CGPA = \frac{C1S1 + C2S2 + C3S3 + C4S4}{C1 + C2 + C3 + C4}$$

where C1, C2, C3,... is the total number of credits for semester I,II,III,... and S1,S2, S3,... is the SGPA of semester I,II,III,.....

12.6. Conversion of GPA/CGPA into a percentage

The performance of students who are pursuing pharmacy programs in the Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal is awarded on a 10-Point-Relative-Letter Grading-Scheme.

In this system the top band (top 10%) of students who score highest marks are placed at A+ which is equivalent to 10 grade point (maximum). Thus, 10 GPA or CGPA is equivalent to 100%. Accordingly, 1 GPA or CGPA is equivalent to 10%.

Based on this, the following formula is applied to convert GPA or CGPA to an appropriate percentage:

Percentage secured by the candidate = GPA or CGPA \times 10

13. Make-up/Supplementary examination

In case, a student fails to secure an E-grade in any theory or practical courses, he/she shall reappear for the end-semester examination of that course. However, his/her marks of the internal assessment shall be carried over, and he/she is entitled for a maximum grade of 'C' only, irrespective of the students' top order performances.

However, the candidates with DT-grade will also be allowed to take this examination provided they meet the eligibility criteria laid for the candidates to appear in the end-semester examinations of the courses of the programs.

Important to Note: A student who once failed (F-grade) or DT (Detained) grade in any course, a maximum of C-grade will only be awarded in subsequent end-semester examinations, irrespective of the student's high performances in that particular course. However, those who miss regular examinations due to valid reasons (I-grade) will be allowed to retain whatever the grades they secure in the make-up/supplementary examinations. In case a candidate with DT-grade reregisters for the course to repeat the entire education process in the subsequent academic year, after paying the required course fee, the DT status in that particular course is removed and he/she is allowed to retain the grades that he/she secures in the end-semester examination.

After the results are declared, grade cards will be issued to each student, which will contain the list of courses for that semester and the grades obtained by the student.

14. Improvement of internal assessment

A student shall have the opportunity to improve his/her performance only once in the sessional exam component of the internal assessment. The re-conduct of the sessional exam shall be completed before the commencement of next end-semester theory examinations.

15. Promotion to the next higher class

A student shall be eligible to carry forward all the courses of I and II semesters till the III/IV semester examinations. However, the results of IV semester (Research project) of the student shall be declared only when the student passes in all the courses of I and II semesters.

16. Declaration of class

The class shall be awarded on the basis of CGPA as follows:

First Class with Distinction	= CGPA of 7.50 and above
First Class	= CGPA of 6.00 to 7.49
Second Class	= CGPA of 5.00 to 5.99

17. Research project work

17.1 Dissertation submission

All the students shall undertake a research project under the supervision of a teacher in semester III and IV and submit a dissertation at the end of the IV semester. Four copies of the dissertation shall be submitted.

Note: If any candidate fails to submit the dissertation on or before the date prescribed, the endsemester examination of such candidate shall be at a later date, which shall not be earlier than 6 months from the date fixed in the first instance.

17.2 Dissertation evaluation

The performance of student in the dissertation work is assessed as per the scheme given in the Table 19.

Table 19. MPharm dissertation evaluation scheme								
Internal Assessment University		ty Examination						
Presentation 1	Presentation 2	Total	Dissertation		Viva Voce		Total	Grand
(III semester)	(IV semester)		Evaluation (300)		Joint			Total
			by Examiners		Evaluation by			
					Internal and			
					External			
					Exami	ners		
					(100))		
			Internal	External	Presenta	Viva-		
					tion	voce		
i	ii	i+ii=A	i	ii	iii	iv	i+ii+i	A+B
							ii+iv	
							=B	
100	100	200	150	150	50	50	400	600

The internal and external examiners appointed by the university shall evaluate the dissertation of the research project separately as per the following evaluation criteria.

Evaluation of Dissertation: For 150 marks each separately by Internal and External Examiners	
	Marks
Objective(s) of the study	25
Literature search	25
Methodology adopted	30
Results and discussions	30
Conclusions and outcomes	20
Bibliography	20
Total	150

Evaluation of Presentation and Viva-voce: For 100 marks jointly by Internal and External Examiners

		Marks
Presentation of work		30
Communication skills		20
	Total	50
Viva-voce		50

18. Award of degree

Candidates who fulfill the requirements mentioned above shall be eligible for award of degree.

19. Duration for completion of the program

The duration for the completion of the program shall be four academic years (double the duration of the prescribed duration). In case, a student is not able to complete the program within this period, the candidate has to reregister for the program.

20. Revaluation of answer papers

There is a provision for revaluation of the answer papers of the end-semester examination as per Manipal Academy of Higher Education policy, however, the candidates have to apply separately by paying the prescribed fee.

21. Re-admission after break of study

The candidate who seeks re-admission to the program after taking a break of the study, has to get the approval from the university.

OUTCOME BASED EDUCATION (OBE) FRAMEWORK

Chapter II

Outcome Based Education (OBE) Framework



MCOPS Vision Mission

Vision:

"Excellence in Pharmaceutical Education and Research"

Mission:

"Marching with the Times"

Quality Policy

- MCOPS is committed towards providing value-based pharmaceutical education to meet industry, hospital and community needs through continuous improvement of infrastructure and facility for learning, practice and research.
- MCOPS shall provide an environment conducive to the development of staff and students.



MPharm Pharmacology Program Educational Objectives

The Department of Pharmacology, Manipal College of Pharmaceutical Sciences, Manipal strives to cultivate a right avenue for self and lifelong learning that would:

PEO	Education Objectives
No	
PEO 1	Build education, not only to secure MPharm degree in
	Pharmacology, but also to develop abilities to assimilate the
	knowledge, skills, and research competencies for application in
	therapeutics and Drug Discovery and Development (DDD).
PEO 2	Hone the acumen and skills required to deliver effective
	services for pharmaceutical industry, academia, and health care
	sector.
PEO 3	Promote a proclivity for higher learning, entrepreneurial
	abilities and pursue a career in research.
PEO 4	Foster the best in-class psychomotor skills to perform
	experiments envisaging the molecular mechanisms of lead
	molecules using platforms such as <i>in-silico</i> tools, cell cultures
	and cell-based assays, animal models using state-of-the-art
	facilities.
PEO 5	Inspire and inculcate pharmacologists to employ ethical and
	good practices to serve for the benefit of society,
	Pharmaceutical Industry and Pharmaceutical Care.


MANIPAL COLLEGE OF PHARMACEUTICAL SCIENCES MANIPAL

(A constituent unit of MAHE, Manipal)

MPharm Pharmacology Program Outcomes (POs)

After successful completion of MPharm Pharmacology program, students will be able to:

PO No	Attribute	Competency
PO 1	Domain knowledge	Comprehend the fundamental knowledge of pharmacy and pharmacology in drug discovery and development process.
PO 2	Problem analysis	Identify, formulate, and analyze complex research problems to reach substantiated conclusions that meet the regulatory requirements in connection with pharmacokinetic, pharmacodynamic and safety issues of the drugs in use and New Chemical Entities (NCE)
PO 3	Design/develop solutions	Design to find solutions for complex research problems through pharmacological strategies and rational drug designs.
PO 4	Conduct investigations of complex problems	Conceptualize and evaluate problems to draw meaningful conclusions through hypothesis, in-silico, in-vitro, in-vivo screening methods, and translational approaches employing appropriate statistical method analysis.
PO 5	Modern tool usage	Handle modern analytical techniques, cell-based assays, statistical packages, and <i>in-silico</i> tools and state-of-the art animal models employed in the fields of pharmacology and toxicology.
PO 6	Business and society	Adopt and facilitate a multidisciplinary approach in allied fields of pharmacy and pharmacology to develop business modules in R&D, scientific consultancy, contract research, etc.
PO 7	Environment and sustainability	Understand the impact of the business solutions in societal and environmental contexts and to demonstrate the knowledge for sustainable development.
PO 8	Ethics	Inculcate and apply ethical principles in different professional activities related to pharmacy and pharmacology.
PO 9	Individual / Teamwork	Function effectively as an individual, and as a member or as a leader in diverse teams, and in multidisciplinary settings for team building capacities.

PO No	Attribute	Competency
PO 10	Communication	Build overall personality by instilling soft skills for the effective communication of ideas and to present the scientific reports in a comprehensive but focussed approach.
PO 11	Project management and finance	Demonstrate the knowledge of financial management to evaluate new and existing projects for effective decision making.
PO 12	Life-long learning	Recognize the need to engage oneself as a life-long learner.

CHAPTER – III

- Course Work
- > COs POs Mapping
- Course Outcomes
- Course Content and Assessment Plan
- > Syllabus in detail

Course	Course Title	Cre	dit hours/	/week	Credit	Marks		
Code		Lecture	Tutorial	Practical	Points			
		(L)	(T)	(P)				
Semester I		1	P					
PQA-MPL101T	Modern Pharmaceutical	4			4	100		
	Analytical Techniques							
PHA-MPL102T	Advanced Pharmacology I	4	1		5	100		
	Pharmacological and	4	1		5	100		
PHA-MPL103T	Toxicological Screening							
	Methods I							
DILA MDI 104T	Cellular and Molecular	4	1		5	100		
PHA-WPL1041	Pharmacology							
PHA-MPL105P	Pharmacology Practical I			12	6	150		
PHA-MPL106S	Seminar*			2	1	100		
	Total	16	3	14	26	650		
Semester II								
PHA-MPL201T	Advanced Pharmacology II	4	1		5	100		
	Pharmacological and	4	1		5	100		
PHA-MPL202T	Toxicological Screening							
	Methods II							
PHA-MPL203T	Principles of Drug Discovery	4	1		5	100		
DILA MDI 204T	Clinical Research and	4	1		5	100		
PHA-MPL2041	Pharmacovigilance							
PHA-MPL205P	Pharmacology Practical II			12	6	150		
PHA-MPL206S	Seminar*			2	1	100		
Total 16 4 14 27 650								
* No end-semester	examination. Only continuous mod	e.						

Course work of MPharm – Pharmacology (MPL) specialization

Course work for MPharm III and IV semesters (Common for all specializations)								
Course	Course Title	Cre	edit hours	Credit	Marks			
Code		Lecture	Tutorial	Practical	Points			
PHA-MRM301T	Research Methodology and	(L) 4	(1)	(P)	4	100		
	Biostatistics*				•	100		
MJC302P	Journal Club*			2	1	100		
MRW401P	Research Work			70	35	600		
	Total 4 72 40 800							
* No end-semester	examination.							

PROGRAM OUTCOMES (POs) AND COURSE OUTCOMES (COs) MAPPING

S No	Course Code	Course Name	Credits	PO1	PO2	PO3	PO4	PO5	PO6	PO7	PO8	PO9	PO10	PO11	PO12
1	PQA-MPL101T	Modern Pharmaceutical Analytical Techniques	4	CO1 CO2 CO3	CO1 CO2 CO3	CO1 CO2 CO3	CO1	CO1 CO2 CO3	CO1	CO1 CO2 CO3	CO1 CO2 CO3	CO3	CO1 CO2 CO3	CO1 CO2 CO3	CO1 CO3
2	PHA-MPL102T	Advanced Pharmacology I	5	CO2 CO3	CO2	CO1 CO4	CO1		CO3						
3	PHA-MPL103T	Pharmacological and Toxicological Screening Methods I	5	CO2	CO3	CO3	CO4		CO1	CO1	CO1				
4	PHA-MPL104T	Cellular and Molecular Pharmacology	5	CO1 CO2 CO3 CO5	CO2	CO3 CO4		CO5							
5	PHA-MPL105P	Pharmacology Practical I	6		CO2	CO2 CO3 CO4	CO3 CO5	CO5	CO4	CO1	CO1	CO3 CO4			
6	PHA-MPL106S	Seminar*	1	CO1	CO1 CO2		CO2 CO5					CO3	CO3 CO4 CO5		CO6
7	PHA-MPL201T	Advanced Pharmacology II	5	CO1 CO3	CO1	CO2	CO2		CO3						
8	PHA-MPL202T	Pharmacological and Toxicological Screening Methods II	5	CO1 CO2 CO3	CO3 CO4	CO1 CO2 CO3	CO3 CO4	CO3 CO4	CO3	CO1	CO1	CO1 CO4		CO3	CO1 CO4
9	PHA-MPL203T	Principles of Drug Discovery	5	CO1	CO2	CO3	CO3 CO4	CO4 CO5	CO5						
10	PHA-MPL204T	Clinical Research and Pharmacovigilance	5	CO1		CO2 CO3	CO3 CO4 CO5		CO4 CO5						
11	PHA-MPL205P	Pharmacology Practical II	6	CO1	CO1 CO2	CO3	CO2 CO3	CO3							
12	PHA-MPL206S	Seminar*	1	CO1	CO1 CO2		CO2 CO5					CO3	CO3 CO4 CO5		CO6
13	PHA-MRM301T	Research Methodology and Biostatistics*	4	CO1		CO1	CO2	CO2						CO1	
14	MJC302P	Journal Club*	1	CO1	CO1		CO1					CO2 CO3	CO3		CO4
15	MRW401P	Research Work	35	CO1	CO1	CO4	CO5	CO5	CO6	CO3	CO3		CO5 CO6	CO2	

CHAPTER III: SYLLABUS MPHARM – PHARMACOLOGY (MPL)

SEMESTER I

PQA-MPL101T: MODERN PHARMACEUTICAL ANALYTICAL TECHNIQUES

COUR	COURSE CODE PQA-MPL 101T							
COUR	RSE TITLE MODERN PHARMACEU (Theory)	TICAL AN	IALYTICAI	L TECH	INIQU	JES		
	SCOPE/SUMMARY	OBJE	CTIVES/COURSE OUTCOMES					
This analyti identif quanti NMR,	subject deals with various advance ical instrumental techniques for fication, characterization, an fication of drugs. Instruments dealt ar Mass spectrometer, IR, HPLC, GC etc.	After com rable to un 1. The th of UV & AE 2. The th of NN 3. The th of Ma 4. The th of of 5. The th	pletion of th derstand: neory, instru- visible spec S. neory, instru- MR spectroso neory, instru- ass spectrom neory, instru- chromatogra neory, instru-	e cours mentati troscop mentati copy. mentati etry. mentati uphic te mentati	e, a str on & on & on & on & chniqu on &	applications applications applications applications applications applications applications applications		
		of therm	electrophore al & immuno	sis, X ologica	RD, l assav	polarimetry,		
	Course Content an	d Assessm	ent Plan		•••••			
Sl No.	Course Content	Syllabus (Chapters	Total Marks	Distribution assess Sessional exam (30 % of total marks of assessment)		of marks of sment End Sem		
		with hours)	of assessment	(30 % a mark assess S1	of total is of nent) S2	exam (70 % of total marks of assessment)		
1	Will know about theory, instrumentation and application of various spectroscopic techniques.	Unit I (15 hrs)	of assessment 30	(30 % c mark assessn S1 10	of total s of nent) S2	exam (70 % of total marks of assessment) 20		
1	Will know about theory, instrumentation and application of various spectroscopic techniques. Will know about the theory instrumentation and applications of NMR spectroscopy.	Unit I (15 hrs) Unit II (8 hrs)	of assessment 30 15	(30 % o mark assessi S1 10 5	of total s of ment) S2	exam (70 % of total marks of assessment) 20 10		
1 2 3	Will know about theory, instrumentation and application of various spectroscopic techniques. Will know about the theory instrumentation and applications of NMR spectroscopy. Will know about the theory instrumentation and applications of Mass spectrometry.	Unit I (15 hrs) Unit II (8 hrs) Unit III (6 hrs)	of assessment 30 15 13	(30 % o mark assessi S1 10 5	f total s of ment) S2	exam (70 % of total marks of assessment) 20 10 10		
1 2 3 4	Will know about theory, instrumentation and application of various spectroscopic techniques. Will know about the theory instrumentation and applications of NMR spectroscopy. Will know about the theory instrumentation and applications of Mass spectrometry. Will know about the theory instrumentation and applications of various chromatographic techniques.	Unit I Unit II (15 hrs) Unit II (8 hrs) Unit III (6 hrs) Unit IV (8 hrs)	of assessment 30 15 13 19	(30 % o mark assessr S1 10 5	f total s of nent) S2 3 4	exam (70 % of total marks of assessment) 20 10 10 15		
1 2 3 4 5	 Will know about theory, instrumentation and application of various spectroscopid techniques. Will know about the theory instrumentation and applications of NMR spectroscopy. Will know about the theory instrumentation and applications of Mass spectrometry. Will know about the theory instrumentation and applications of various chromatographic techniques. Will know about the theory, applications of electrophoresis, X-ray crystallography, Potentiometry Thermal techniques and Immuno assays 	 Unit I (15 hrs) Unit II (8 hrs) Unit III (6 hrs) Unit IV (8 hrs) Unit V (15 hrs) 	of assessment 30 15 13 19 28	(30 % o mark assessi S1 10 5	f total s of ment) S2 3 4 8	exam (70 % of total marks of assessment) 20 10 10 15 20		

PQA-MPL101T: MODERN PHARMACEUTICAL ANALYTICAL TECHNIQUES

THEORY

1.a. UV-Visible Spectroscopy: Introduction, theory, laws, instrumentation associated with UV-Visible spectroscopy, choice of solvents and solvent effect and applications of UV-Visible spectroscopy, Difference/ Derivative spectroscopy.

b. IR Spectroscopy: Theory, modes of molecular vibrations, sample handling, instrumentation of dispersive and Fourier-Transform IR spectrometer, factors affecting vibrational frequencies and applications of IR spectroscopy. 5 hrs

c. Spectroflourimetry: Theory of fluorescence, factors affecting fluorescence, quenchers, instrumentation and applications of fluorescence spectrophotometry.
 2 hrs

d. Flame Emission Spectroscopy and atomic absorption spectroscopy: Principle, instrumentation, interferences and applications.3 hrs

2. NMR Spectroscopy: Quantum numbers and their role in NMR, principle, instrumentation, solvent requirement in NMR, relaxation process, NMR signals in various compounds, chemical shift, factors influencing chemical shift, Spin-Spin coupling, coupling constant, nuclear magnetic double resonance, brief outline of principles of FT-NMR and 13C NMR. Applications of NMR spectroscopy. 8 hrs

3. **Mass Spectroscopy**: Principle, theory, instrumentation of mass spectroscopy, different types of ionization like electron impact, chemical, field, FAB and MALDI, APCI, ESI, APPI analyzers of quadrupole and time of flight, mass fragmentation and its rules, meta stable ions, isotopic peaks and applications of mass spectroscopy. **6 hrs**

4. **Chromatography**: Principle, apparatus/instrumentation, chromatographic parameters, factors affecting resolution and applications of the following:

a) Planar chromatography-Paper, Thin layer chromatography and High performance thin layer chromatography b) Ion exchange chromatography c) Column chromatography d) Gas chromatography e) High performance liquid chromatography and ultra-high performance liquid chromatography f) Affinity chromatography g) Gel chromatography.
8 hrs

5. Other Analytical Techniques

a. Electrophoresis: Principle, instrumentation, working conditions, factors affecting separation and applications of the following: a) Paper electrophoresis b) Gel electrophoresis
 c) Capillary electrophoresis d) Zone electrophoresis e) Moving boundary electrophoresis f) Iso electric focusing.
 3 hrs

b. X-ray Crystallography: Different X-ray diffraction methods, Bragg's law	, Rotating
crystal technique, X-ray powder technique, types of crystals and applications	of X-ray
diffraction.	2 hrs
c. Potentiometry: Principle and application of potentiometry.	2 hrs
d. Thermal Techniques: Principle and application of Differential Scanning Ca	alorimetry,
Differential Thermal Analysis and Thermo Gravimetric Analysis.	5 hrs
e. Immunological Assays: RIA (Radio immuno assay), ELISA.	3 hrs

REFERENCES

- Spectrometric Identification of Organic Compounds, Robert M Silverstein, 6th edition, John Wiley & Sons, 2004.
- Principles of Instrumental Analysis, Doglas A Skoog, F. James Holler, Timothy A. Nieman, 5th edition, Eastern Press, Bangalore, 1998.
- 3. Instrumental Methods of Analysis, Willards, 7th edition, CBS Publishers.
- 4. Practical Pharmaceutical Chemistry, Beckett and Stenlake, Vol II, 4th edition, CBS Publishers, New Delhi, 1997.
- 5. Organic Spectroscopy, William Kemp, 3rd edition, ELBS, 1991.
- Quantitative Analysis of Drugs in Pharmaceutical Formulation, PD Sethi, 3rd edition, CBS Publishers, New Delhi, 1997.
- 7. Pharmaceutical Analysis-Modern Methods, Part B, J W Munson, Volume11, Marcel Dekker Series.
- 8. Introduction to Spectroscopy, Donald L Pavia. 8th edition, CENGAGE Learning, USA
- 9. Contemporary Practice of Chromatography, Poole, Colin F and Sheila A Schuette, Elsevier Science Publishers.
- 10. Remington: The Science and Practice of Pharmacy, latest edition, Pharmaceutical Press, UK.
- 11. Quantitative Analysis of Pharmaceutical Formulations by HPTLC, PD Sethi, CBS Publishers, New Delhi.

SEMESTER I

PHA-MPL102T: ADVANCED PHARMACOLOGY I

COU	RSE CODE	PHA- MPL 102T									
COU	RSE TITLE	ADVANCED PHARMAC	COLOGY I	(Theory)							
	SCOPE	/SUMMARY	OBJECTIVES/COURSE OUTCOMES								
The basic and used Besic unde mech	subject is des knowledge in to impart rece for the treatn des, this subje rstand the con hanisms involve	signed to strengthen the the field of pharmacology nt advances in the drugs nent of various diseases. act helps the students to cepts of drug action and ed.	 e Upon completion of the course, the student shat be able to: s 1. Discuss the pathophysiology an pharmacotherapy of certain diseases o 2. Explain the mechanism of drug actions a cellular and molecular level 3. Understand the adverse effects contraindications and clinical uses of drug used in treatment of diseases 								
		Course Content and	Assessmen	ıt Plan							
SI. No.	C	ourse Content	Syllabus (Chapters or Units with hours)	Total Marks of assessment	Distribution asses Sessional exam (30 % of total marks of assessment)		Distributio asses Sessional exam (30 % of total marks of assessment)		Distribution asses Sessional exam (30 % of total marks of assessment)		n of marks of sment End Sem exam (70 % of total marks of assessment)
1	The students the dynamics of linear and models, relati concentration the types, s families of red	should be able to explain of drug ADME, concepts non-linear compartment onship between drug and effect, and compare tructural and functional ceptors.	Unit I (10 hrs)	22	7		15				
2	The learners neurohumoral autonomic nervous syst cholinergic tra	should be able to explain transmission in nervous system, central em, Non-adrenergic non- ansmission etc.	Unit II (10 hrs)	23	8		15				
3	The students a pharmacology of parasympa lytics, sympat lytics, ge anesthetics, s -depressants,	should be able to learn the thomimetics & homimetics & eneral and local edatives & hypnotics, anti- antipsychotics, anti-	Unit III a, b, c (22 hrs)	40		15	25				

	epileptics, narcotic & non-narcotic					
	analgesics, diuretics, antihypertensives,					
	anti-ischemics, anti-arrhythmics, drugs					
	for heart failure and hyperlipidemia					
	hematinics, coagulants, anticoagulants,					
	fibrinolytics and antiplatelet drugs.					
4	The candidates should be able to explain the physiological and pathological role of histamine, serotonin, kinins, prostaglandins, opioid autacoids, and pharmacological applications of antihistamines, 5HT antagonists.	Unit III d (10 hrs)	20		-	20
Total Marks of Assessmen			105	15	15	75

PHA-MPL102T: ADVANCED PHARMACOLOGY I

THEORY

1. General Pharmacology

a. Pharmacokinetics: The dynamics of drug absorption, distribution, biotransformation and elimination. Concepts of linear and non-linear compartment models. Significance of Protein binding.

b. Pharmacodynamics: Mechanism of drug action and the relationship between drug concentration and effect. Receptors, structural and functional families of receptors, quantification of drug receptor interaction and elicited effects.

2. Neurotransmission

- a. General aspects and steps involved in neurotransmission.
- b. Neurohumoral transmission in autonomic nervous system (Detailed study about neurotransmitters- adrenaline and acetyl choline.

c. Neurohumoral transmission in central nervous system (Detailed study about neurotransmitters- histamine, serotonin, dopamine, GABA, glutamate and glycine).

d. Non adrenergic non cholinergic transmission (NANC). Co-transmission

3. Systemic Pharmacology

A detailed study on pathophysiology of diseases, mechanism of action, pharmacology and toxicology of existing as well as novel drugs used in the following systems

a. Autonomic Pharmacology: Parasympathomimetics and lytics, sympathomimetics and lytics, agents affecting neuromuscular junction.
 6 hrs

32 hrs

10 hrs

10 hrs

52 hrs

- b. Central nervous system Pharmacology: General and local anesthetics, Sedatives and hypnotics, drugs used to treat anxiety, depression, psychosis, mania, epilepsy, neurodegenerative diseases, Narcotic and non-narcotic analgesics.
 6 hrs
- c. Cardiovascular Pharmacology: Diuretics, antihypertensives, antiischemics, anti- arrhythmics, drugs for heart failure and hyperlipidemia. Hematinics, coagulants, anticoagulants, fibrinolytics and antiplatelet drugs. 10 hrs
- d. Autacoid Pharmacology: The physiological and pathological role of Histamine, Serotonin, Kinins, Prostaglandins, Opioid autocoids. Pharmacology of antihistamines, 5HT antagonists.
 10 hrs

REFEERENCES

- 1. The Pharmacological Basis of Therapeutics, Goodman and Gillman's (Latest edition).
- Principles of Pharmacology. The Pathophysiologic basis of drug Therapy by David E Golan, Armen H, Tashjian Jr, Ehrin J, Armstrong, April W, Armstrong, Wolters, Kluwer-Lippincott Williams & Wilkins Publishers.
- 3. Basic and Clinical Pharmacology by B.G Katzung, (Latest edition).
- 4. Hand book of Clinical Pharmacokinetics by Gibaldi and Prescott. (Latest edition).
- 5. Applied biopharmaceutics and Pharmacokinetics by Leon Shargel and Andrew B.C.Yu.
- 6. Graham Smith. Oxford textbook of Clinical Pharmacology.
- 7. Avery Drug Treatment.
- 8. Dipiro Pharmacotherapy A Pathophysiological approach.
- 9. Green Pathophysiology for Pharmacists.
- 10. Robbins & Cortan Pathologic Basis of Disease, 9th Ed. (Robbins Pathology)
- 11. A Complete Textbook of Medical Pharmacology by Dr. S.K Srivastava published by APC Avichal Publishing Company.
- 12. KD. Tripathi. Essentials of Medical Pharmacology.
- Modern Pharmacology with Clinical Applications, Craig Charles R. & Stitzel Robert E., Lippincott Publishers.
- Clinical Pharmacokinetics & Pharmacodynamics: Concepts and Applications Malcolm Rowland and Thomas N. Tozer, Wolters Kluwer, Lippincott Williams & Wilkins Publishers.
- 15. Applied biopharmaceutics and Pharmacokinetics, Pharmacodynamics and Drug metabolism for industrial scientists.
- 16. Modern Pharmacology, Craig CR. & Stitzel RE, Little Brown & Company.

MPHARM – PHARMACOLOGY (MPL) SEMESTER I

PHA-MPL103T: PHARMACOLOGICAL AND TOXICOLOGICAL SCREENING METHODS I

CC	OURSE CODE	PHA-MPL 103T					
CC	OURSE TITLE	PHARMACOLOGICAL A METHODS I (Theory)	AND TOXICO	LOGICAI	L SCRE	ENING	
	SCOPE/S	SUMMARY	OBJECTI	VES/COU	URSE (OUTCO	OMES
Th on ex an Th un an va ev	his subject is design preclinical evaluati perimental techniqu d development. his subject also he iderstand the main imals as per the guide rious <i>in-vitro</i> ar aluation procedures.	ed to impart knowledge on of drugs and recent es in the drug discovery elps the students to ntenance of laboratory elines, basic knowledge of nd <i>in-vivo</i> preclinical	 Upon completion of this course, the student should be able to: 1. Appraise the regulations and ethical requirement for the usage of experimental animals. 2. Describe the various animal models and screening techniques used in drug discovery process. 3. Describe the various newer screening methods involved in the drug discovery process. 4. Appreciate and correlate the preclinical data 				
		Course Content and	d Assessment P	lan			
SI No.	Cour	se Contents	Syllabus (Chapters or Units with hours)	Total Marks of assessment	Distril Sessiona (30 % d mari assess S1	bution of assessm al exam of total ks of ment) S2	Emarks of ent End Sem exam (70 % of total marks of assessment)
1	The students will maintenance, applicate blood withdrawal laboratory and per regulatory guide they will learn the of Practice and bioassay	study the production, tion, anesthesia, euthanasia, techniques of common transgenic animals, as lines (CPCSEA). Besides, concept of Good Laboratory	Unit I (10 hrs)	17	7		10
2	Learn general clinical methods to te ANS.	principles and pre- est drugs acting on CNS and	Unit II (12 hrs)	23	8		15
3	Study the preclinical to respiratory, repr fever, pain and inflan	methods to test drugs related roductive, gastrointestinal, numatory disorders.	Unit III (10 hrs)	22		7	15
4	Learn general princip to test drugs metabolic disorders, o	les and pre-clinical methods for cardiovascular and cancer and hepatic disorders	Unit IV (10 hrs)	23		8	15

5	Study pre-clinicalscreeningtechniques for immunomodulatorydrugs.Understand and learn immunoassay technique toassess different biomarkers. Besides, study oflimitationsofanimalexperimentsandextrapolation of <i>in vitro</i> data to pre-clinical andpre-clinical to humans.	Unit V (10 hrs)	20			20
	Total Marks	of Assessment	105	15	15	75

PHA-MPL103T: PHARMACOLOGICAL AND TOXICOLOGICAL SCREENING METHODS I

THEORY

52 hrs

1. Laboratory Animals

10 hrs

Common laboratory animals: Description, handling and applications of different species and strains of animals. Transgenic animals: Production, maintenance and applications. Anaesthesia and euthanasia of experimental animals. Maintenance and breeding of laboratory animals. CPCSEA guidelines to conduct experiments on animals. Good laboratory practice. Bioassay-Principle, scope and limitations and methods.

2. Preclinical screening of new substances for the pharmacological activity using *in vivo, in vitro*, and other possible animal alternative models.
12 hrs
General principles of preclinical screening.

CNS Pharmacology: behavioral and muscle co-ordination, CNS stimulants and depressants, anxiolytics, anti-psychotics, anti-epileptics and nootropics. Drugs for neurodegenerative diseases like Parkinsonism, Alzheimer's and multiple sclerosis.

Drugs acting on Autonomic Nervous System.

3. Preclinical screening of new substances for the pharmacological activity using *in vivo, in vitro*, and other possible animal alternative models.
10 hrs
Respiratory Pharmacology: anti-asthmatics, drugs for COPD and anti allergics.
Reproductive Pharmacology: Aphrodisiacs and antifertility agents
Analgesics, anti-inflammatory and antipyretic agents.
Gastrointestinal drugs: anti-ulcer, anti -emetic, antidiarrheal and laxatives.

4. Preclinical screening of new substances for the pharmacological activity using *in vivo, in vitro*, and other possible animal alternative models.10 hrs

Cardiovascular Pharmacology: antihypertensives, antiarrhythmics, antianginal, antiatherosclerotic agents and diuretics. Drugs for metabolic disorders like anti-diabetic, antidyslipidemic agents.

Anti-cancer agents. Hepatoprotective screening methods.

5. Preclinical screening of new substances for the pharmacological activity using *in vivo, in vitro*, and other possible animal alternative models.
10 hrs
Immunomodulators, Immunosuppressants and immunostimulants

General principles of immunoassay: theoretical basis and optimization of immunoassay, heterogeneous and homogenous immunoassay systems. Immunoassay methods evaluation, protocol outline, objectives and preparation. Immunoassay for digoxin and insulin, Limitations of animal experimentation and alternate animal experiments. Extrapolation of *in vitro* data to preclinical and preclinical data to humans

REFERENCES

- 1. Biological standardization by J.H. Burn, D.J. Finney, and I.G. Goodwin.
- 2. Screening methods in Pharmacology by Robert Turner. A.
- 3. Evaluation of drugs activities by Laurence and Bachrach.
- 4. Methods in Pharmacology by Arnold Schwartz.
- 5. Fundamentals of experimental Pharmacology by M.N. Ghosh.
- 6. Pharmacological experiment on intact preparations by Churchill Livingstone.
- 7. Drug discovery and Evaluation by Vogel H.G.
- 8. Experimental Pharmacology by R.K. Goyal.
- 9. Preclinical evaluation of new drugs by S.K. Gupta
- 10. Handbook of Experimental Pharmacology, SK. Kulkarni.
- 11. Practical Pharmacology and Clinical Pharmacy, SK. Kulkarni, 3rd Edition.
- 12. David R. Gross. Animal Models in Cardiovascular Research, 2nd Edition, Kluwer Academic Publishers, London, UK.
- 13. Screening Methods in Pharmacology, Robert A. Turner.
- 14. Rodents for Pharmacological Experiments, Dr. Tapan Kumar Chatterjee.
- 15. Practical Manual of Experimental and Clinical Pharmacology by Bikash Medhi (Author), Ajay Prakash (Author).

SEMESTER I

PHA-MPL104T: CELLULAR AND MOLECULAR PHARMACOLOGY

COU	RSE CODE	PHA-MPL 104T						
COU	RSE TITLE	CELLULAR AND MO	LECULAR P	HARMAC	OLOGY	(The	eory)	
	SCOPE /	SUMMARY	OBJECTIVES/COURSE OUTCOMES					
This know cellul the in drugs This stude disco	subject im vledge of the st lar components nteraction of s. information ent to apply t overy process.	parts a fundamental ructure and functions of and helps to understand these components with will further help the he knowledge in drug	 I Upon completion of the course, the student shall be able to: I. Explain the receptor signal transduction processes 2. Describe the molecular pathways affected be drugs 3. Appreciate the applicability of molecular pharmacology and biomarkers in dru discovery process 4. Demonstrate molecular biology technique as applicable for pharmacology. 				tudent shall transduction s affected by f molecular rs in drug techniques	
	Course Content and Assessment Plan							
SI No.	C	ourse Content	Syllabus (Chapters or Units with hours)	Total Marks of assessment	Session exam (30 % of marks assessm S1	assess nal n <i>i</i> <i>total</i> of <i>ent</i>) S2	End Sem exam (70 % of total marks of assessment)	
1	Student will I and functiona organelles, ce ations of gene	earn about the structural al aspects of cell and its allular events, and applic e sequencing.	Unit I (10 hrs)	22	7		15	
2	Student various types roles of secon relation to cel	will understand the of receptors and dary messengers in lular function.	Unit II (12 hrs)	23	8		15	
3	Student the principles of different ge tools.	will comprehend and applications enomic and proteomic	Unit III (10 hrs)	17		7	10	
4	Student pharmacogenc application.	will understand omics and its	Unit IV (10 hrs)	23		8	15	

	Further, applications of genomics, proteomics, metabolomics and functionomics will be grasped.					
5	Student will learn the basics, types, procedure of cell culture and the related instruments required for sub- culturing. Principles and applications of various cell-based assays and biosimilar will be understood.	Unit V (10 hrs)	20			20
Total Marks of Assessment			105	15	15	75

PHA-MPL104T: CELLULAR AND MOLECULAR PHARMACOLOGY

THEORY

1. Cell biology

Structure and functions of the cell and its organelles, Genome organization. Gene expression and its regulation, importance of siRNA and micro RNA, gene mapping and gene sequencing, Cell cycles and its regulation. Cell death- events, regulators, intrinsic and extrinsic pathways of apoptosis. Necrosis and autophagy.

2. Cell signaling

Intercellular and intracellular signaling pathways.

Classification of receptor family and molecular structure ligand-gated ion channels, G-protein coupled receptors, tyrosine kinase receptors and nuclear receptors.

Secondary messengers: cyclic AMP, cyclic GMP, calcium ion, inositol 1, 4, 5-trisphosphate, (IP3), NO, and diacylglycerol.

Detailed study of following intracellular signaling pathways: cyclic AMP signaling pathway, mitogen-activated protein kinase (MAPK) signaling, Janus kinase (JAK)/signal transducer and activator of transcription (STAT) signaling pathway.

3. Principles and applications of genomic and proteomic tools 10 hrs

DNA electrophoresis, PCR (reverse transcription and real time), Gene sequencing, micro array technique, SDS page, ELISA and western blotting, recombinant DNA technology and gene therapy, Basic principles of recombinant DNA technology-Restriction enzymes, various types of vectors. Applications of recombinant DNA technology.

Gene therapy- Various types of gene transfer techniques, clinical applications and recent advances in gene therapy.

Page | 49

10 hrs

52 hrs

12 hrs

4. Pharmacogenomics

Gene mapping and cloning of disease gene. Genetic variation and its role in health/ pharmacology, Polymorphisms affecting drug metabolism, Genetic variation in drug transporters, Genetic variation in G-protein coupled receptors, Applications of proteomics science: Genomics, proteomics, metabolomics, functionomics, nutrigenomics. **Immunotherapeutics,** Types of immunotherapeutics, humanised antibody therapy, immunotherapeutics in clinical practice.

5. Cell culture techniques and Biosimilars

Basic equipment used in a cell culture lab. Cell culture media, various types of cell culture, general procedure for cell cultures; isolation of cells, subculture, cryopreservation, characterization of cells and their application. Principles and applications of cell viability assays, glucose uptake assay, Calcium influx assays. Principles and applications of flow cytometry. Biosimilars

REFERENCES

- 1. The Cell, A Molecular Approach. Geoffrey M Cooper.
- Pharmacogenomics: The Search for Individualized Therapies. Edited by J. Licinio and M -L. Wong.
- 3. Handbook of Cell Signaling (Second Edition) Edited by Ralph A. et al.
- 4. Molecular Pharmacology: From DNA to Drug Discovery. John Dickenson et al.
- 5. Basic Cell Culture protocols by Cheril D. Helgason and Cindy L. Miller.
- 6. Basic Cell Culture (Practical Approach) by J. M. Davis (Editor).
- 7. Animal Cell Culture: A Practical Approach by John R. Masters (Editor).
- 8. Current protocols in molecular biology vol I to VI edited by Frederick M. Ausuvel et al.

10 hrs

10 hrs

SEMESTER I

PHA-MPL105P: PHARMACOLOGY PRACTICAL I

CC	DURSE CODE PHA-MPL 105P								
CC	OURSE TITLE	PHARMACO	OLOGY I	PRACTICAL	L - I (Practi	ical)			
	SCOPE/SUMMA	RY	(OBJECTIVE	ES/COUR	SE OUTCOM	IES		
Th	is subject is designed to	gain practical	Upon co	ompletion of	this cours	se, the student	t should be		
ski	lls on various precl	linical testing	able to:						
pro	ocedures of drugs	and recent	1. Unde	erstand the e	ethical cor	sideration gov	verning the		
ex	perimental techniques	anim	al experimer	ntation and	Learn the be	st practices			
dis	covery and development	t.	for s	afe handling	of animal	s. Explain the	regulations		
			and e	ethical requir	ement for t	the usage of ex	sperimental		
Th	is subject also helps the	e students to	anim	als.	1 (.1	1 ()		
un	derstand the maint	tenance of	2. Expe	eriment and	analyze to	o identify, an	d estimate		
lac	oratory animals as per tr	ie guidennes,	pnari	maceutical a	cuve ingre		ation using		
in Ua	in vivo proglinical avaluation 2. Plan design and interment proglinical avaluation								
nro	procedures techniques for drug discovery process								
pro	Jeeures.		4 Criti	cally analyze	the variou	is animal mod	els used in		
			drug	discovery pr			iens used in		
			5. Corr	5. Correlate the preclinical data to humans					
	Course Content and Assessment Plan								
	Distribution of marks of								
			Syllabus		assessi	nent			
SI				(Chapters or	Total Morks of	Sessional exam $(25\% \text{ of total})$	End Sem		
No.	Course		Units with	assessment	marks of	exam (75 % of total			
			hours)		assessment)	marks of			
						S1	assessment)		
	Experiment and analy	yze to ident	ify, and						
	estimate pharma	aceutical	active	Experiments					
	ingredients/formulation	and							
1	biological samples usin	ig various inst	rumental	1 to	39	9	30		
	techniques like	UN	/-V1s1ble	6; 27 and					
	spectrophotometer, sin	Cas abromat	stimation	$\frac{29}{(49 \text{ hms})}$					
	fluorimetry flame phot	, Gas cilioillat	ograpny,	(48 IIIS)					
	Inculcate best practice	$\frac{1}{1}$ s and skills to	handle						
	with-draw blood anest	betize euthani	ize small						
	laboratory animals.	liouzo, cumun		Experiments					
2	Functional observation	battery test;	Evaluate	7 to 15	75	17	58		
1	and interpret test compounds action on			(90 hrs)	1	1			
	and interpret test co	ompounds ac	ction on	(50 m 5)					

	CNS activity, diuretic, local anesthetic, ulcer, and blood sugar level.				
3	Isolation, identification and estimation of DNA, RNA, proteins by suitable methods. Demonstrate various in-vitro procedures used to understand molecular aspects of drug action like PCR, western blotting, enzyme-based assays, ELISA, Electrophoresis, fluorescent- based assays, and statistical software for Data analysis	Experiments 16 to 26 (18 hrs)	16	4	12
	Total Marks of Assessment			30	100

PHA-MPL105P: PHARMACOLOGY PRACTICAL I

- 1. Analysis of pharmacopeial compounds and their formulations by UV-Vis spectrophotometer.
- 2. Simultaneous estimation of multi-component formulations by UV spectrophotometry.
- 3. Experiments based on HPLC.
- 4. Experiments based on Gas Chromatography.
- 5. Estimation of riboflavin/quinine sulphate by fluorimetry.
- 6. Estimation of sodium/potassium by flame photometry.
- 7. Handling of laboratory animals.
- 8. Various routes of drug administration.
- 9. Techniques of blood sampling, anesthesia and euthanasia of experimental animals.
- 10. Functional observation battery tests (modified Irwin test).
- 11. Evaluation of CNS stimulant, depressant, anxiogenics and anxiolytic, anticonvulsant activity.
- 12. Evaluation of analgesic, anti-inflammatory, local anesthetic, mydriatic and miotic activity.
- 13. Evaluation of diuretic activity.
- 14. Evaluation of antiulcer activity by pylorus ligation method.
- 15. Oral glucose tolerance test.
- Isolation and identification of DNA from various sources (Bacteria, Cauliflower, Onion, Goat liver).
- 17. Isolation of RNA from yeast.
- Estimation of proteins by Bradford/Lowry method in biological samples. Estimation of RNA/DNA by UV Spectroscopy.

- 19. Gene amplification by PCR.
- 20. Protein quantification by Western Blotting.
- 21. Enzyme based *in-vitro* assays (MPO, AChEs, α amylase, α glucosidase).
- 22. Cell viability assays (MTT/Trypan blue/SRB).
- 23. DNA fragmentation assay by agarose gel electrophoresis.
- 24. DNA damage study by Comet assay.
- 25. Apoptosis determination by fluorescent imaging studies.
- 26. Pharmacokinetic studies and data analysis of drugs given by different routes of administration using software.
- 27. Enzyme inhibition and induction activity.
- 28. Extraction of drugs from various biological samples and estimation of drug in biological fluids using different analytical techniques (UV).
- 29. Extraction of drugs from various biological samples and estimation of drug in biological fluids using different analytical techniques (HPLC).

REFERENCES

- 1. CPCSEA, OECD, ICH, USFDA, Schedule Y, EPA guidelines.
- 2. Fundamentals of experimental Pharmacology by M.N. Ghosh.
- 3. Handbook of Experimental Pharmacology by S.K. Kulkarni.
- 4. Drug discovery and Evaluation by Vogel H.G.
- 5. Spectrometric Identification of Organic compounds Robert M Silverstein.
- Principles of Instrumental Analysis Doglas A Skoog, F. James Holler, Timothy A. Nieman.
- 7. Vogel's Textbook of quantitative chemical analysis Jeffery, Basset, Mendham, Denney.
- 8. Basic Cell Culture protocols by Cheril D. Helgason and Cindy L.Mille.
- 9. Basic Cell Culture (Practical Approach) by J. M. Davis (Editor).
- 10. Animal Cell Culture: A Practical Approach by John R. Masters (Editor).
- Practical Manual of Experimental and Clinical Pharmacology by Bikash Medhi (Author),
 Ajay Prakash (Author) Jaypee Brothers' Medical Publishers Pvt. Ltd.

SEMESTER I

PHA-MPL106S: SEMINAR IN PHARMACOLOGY

COUR	SE CODE	PHA- MPL 106	ōS				
COUR	SE TITLE	SEMINAR IN I	PHARMACOLOGY				
	SCOPE/SUM	MARY	OBJECTIVES	COURSE OU	JTCOMES		
The su environ the stu- openne and a student Pharma	bject is design nment where tea dents with a cr ess to fortify th academic writing ts in the acology.	ed to create an achers provide ritical eye and ne presentation ing skills of field of	 Upon completion of able to: 1. Develop skills to information, and pharmacology 2. Learn to organize of using audio-visual at 3. Acquire communicated and the second structure of the second structu	the course, the to gather, o defend a complex pharm aids. ation and prese respond peers and s e-up on the n. of upgradation	e student shall be organize, deliver given topic in nacology concepts entation skills. to the stand scientific subject of on of knowledge		
		Course Co	antent and Assessment Plan				
SI No.	Course	Contents	Hours	Total Marks of assessment	Marks End Sem exam		
1	The students s to develop sk organize, information, a given t pharmacology	should be able fills to gather, deliver and defend a topic in	2 hours/week	100	No end-semester examination. Only continuous mode.		

SEMESTER II

PHA-MPL201T: ADVANCED PHARMACOLOGY II

COU	OURSE CODE PHA- MPL201T							
COU	RSE TITLE	ADVANCED PHA	ARMACOL	OGY II (T	heory)			
	SCOPE/SUM	MARY	OBJECTIVES/COURSE OUTCOMES					
The basic phart adva of va helps conc invol	he subject is designed to strengthen the asic knowledge in the field of narmacology and to impart recent dvances in the drugs used for the treatment is various diseases. Besides, this subject elps the students to understand the oncepts of drug action and mechanisms volved. Upon completion of the course, the student shall be able to: 2. Discuss 1. Explain the mechanism of drug actions at cellular and molecular level. 2. Discuss the pathophysiology and pharmacotherapy of certain diseases. 3. Understand the adverse effects, contraindications and clinical uses of drugs used in treatment of diseases. Course Content and Assessment Plan Distribution of marks of						lent shall be ns at cellular gy and raindications treatment of	
					Distrib	oution of	f marks of	
SI No.	Course	Content	Syllabus (Chapters or Units with hours)	Total Marks of assessment	Sessional (30 % of tota of assessm S1	exam l marks pent) S2	End Sem exam (70 % of total marks of assessment)	
1	Understand the a molecular mechan therapeutic uses related drugs.	dvanced cellular/ nisms, safety and of hormones and	Unit I (10 hrs)	17	7		10	
2	Study the actions, and therapeutic p classes of antimic specific chemoth used against infec	resistance, safety, profile of different probials. Study the herapeutic agents tion and cancer.	Unit II (12 hrs)	23	8		15	
3	Learn the actio involved in im- reactions, and immunomodulato about respiratory of treatment guidelin	ns of mediators nune & allergic role of ry drugs. Study disorders and their tes.	Unit III (10 hrs)	22		7	15	
4	Study the actions of drugs used for gastro-intestinal of the advance know to effect of drug timing of drug adu	and safety profile the treatment of lisorders. Acquire wledge pertaining s varying due to ministration.	Unit IV (10 hrs)	23		8	15	
5	Learn how the ox free radicals in pathological of therapeutic	xidative stress and volved in various conditions and role of	Unit V (10 hrs)	22		-	20	

antioxidants. Study the advancements in therapy of cancer					
diabetes mellitus, Alzheimer's and					
Parkinson's disease.					
Total Marks of A	Assessment	105	15	15	75

PHA-MPL201T: ADVANCED PHARMACOLOGY II

THEORY

1. Endocrine Pharmacology

Molecular and cellular mechanism of action of hormones such as growth hormone, prolactin, thyroid, insulin and sex hormones, Anti-thyroid drugs, Oral hypoglycemic agents, Oral contraceptives, Corticosteroids. Drugs affecting calcium regulation.

2. Chemotherapy

Cellular and molecular mechanism of actions and resistance of antimicrobial agents such as ß-lactams, aminoglycosides, quinolones, macrolide antibiotics. antifungal, antiviral, and anti-TB drugs. Drugs used in Protozoal Infections, Drugs used in the treatment of Helminthiasis, Chemotherapy of cancer.

3. Inflammation, Respiratory and Immunopharmacology 10 hrs

Cellular and biochemical mediators of inflammation and immune response. Allergic or hypersensitivity reactions. Pharmacotherapy of asthma and COPD. Immunopharmacology, Immunosuppressants and Immunostimulants.

4. GIT and Chronopharmacology

Antiulcer drugs, Prokinetics, antiemetics, anti-diarrhoeals and drugs for constipation and drugs for irritable bowel syndrome. Chronopharmacology. Biological and circadian rhythms, applications of chronotherapy in various diseases like cardiovascular disease, diabetes, asthma and peptic ulcer

5. Free radical Pharmacology

Generation of free radicals, role of free radicals in etiopathology of various diseases such as diabetes, neurodegenerative diseases, and cancer. Protective activity of certain important antioxidants Recent advances in the treatment of Alzheimer's disease, Parkinson's disease, Cancer, Diabetes mellitus.

12 hrs

10 hrs

10 hrs

10 hrs

52 hrs

REFERENCES

- 1. The Pharmacological basis of therapeutics Goodman and Gilman.
- Principles of Pharmacology. The Pathophysiologic basis of drug therapy by David E. Golan et al.
- 3. Basic and Clinical Pharmacology by B.G. Katzung.
- 4. Pharmacology by H.P. Rang and M.M. Dale.
- 5. Handbook of Clinical Pharmacokinetics by Gibaldi and Prescott.
- 6. Text book of Therapeutics, drug and disease management by E T. Herfindal and Gourley.
- 7. Applied biopharmaceutics and Pharmacokinetics by Leon Shargel and Andrew B.C. Yu.
- 8. Handbook of Essential Pharmacokinetics, Pharmacodynamics and Drug Metabolism for Industrial Scientists.
- 9. Robbins & Cortan Pathologic Basis of Disease, 9th Ed. (Robbins Pathology).
- 10. A Complete Textbook of Medical Pharmacology by Dr. S.K Srivastava published by APC Avichal Publishing Company.
- 11. KD. Tripathi. Essentials of Medical Pharmacology.
- Principles of Pharmacology. The Pathophysiologic basis of drug Therapy by David E Golan, Armen H, Tashjian Jr, Ehrin J, Armstrong, April W, Armstrong, Wolters, Kluwer-Lippincott Williams & Wilkins Publishers.

SEMESTER II

PHA-MPL202T: PHARMACOLOGICAL AND TOXICOLOGICAL SCREENING METHODS II

COU	RSE CODE PHA-MPL202T								
COU	RSE TITLE PHARMACOLOGICA METHODS II (Theory	AL AND TO)	XICOLOC	SICAL	SCREE	INING			
	SCOPE/SUMMARY	OBJEC	TIVES/CO	OURSE	E OUTO	COMES			
This precl evalu entity stude toxic	subject imparts knowledge on the inical safety and toxicological attion of drug & new chemical y. This knowledge will make the ent competent in regulatory ological evaluation.	Upon compl be able to: 1. Understan safety phar 2. Explain th 3. Understan drug and drug deve 4. Demonstr required alternativ developm	etion of the d and apply macology he various nd the cond apply it's d elopment p rate the the to conduct re methods nent studies	e course ly the p and tox types o cepts of enabling rocess. coretical t toxico of anin s.	e, the stu rinciple icologic f toxicit investig g studies l and pr okinetic mal tox	adent shall s of GLP in cal studies cy studies. gational new s to meet the actical skills studies and icity in drug			
	Course Content and Assessment Plan								
Sl No.	Course Content	Syllabus (Chapters or Units with hours)	Total Marks of assessment	Dist Session (30 %) mart assess S1	ribution assess al exam of total ks of ment) S2	of marks of ment End Sem exam (70 % of total marks of assessment)			
1	Learn the general aspect of toxicology, regulatory guidelines, Good Laboratory Practices, and develop SOP's for the conduct of regulatory toxicity.	Unit I (10 hrs)	18	8		10			
2	Understand the procedures involved in the toxicity studies, eye irritation, skin sensitization, dermal irritation, and dermal toxicity studies according to OECD guidelines.	Unit II (10 hrs)	22	7		15			
3	Learn the protocols of special toxicity studies such as reproductive, teratogenicity and genotoxicity studies etc.	Unit III (10 hrs)	22		7	15			

4	Learn the IND enabling studies requirements, significance, industry perspective of IND submission, safety pharmacology related to CVS, CNS, respiratory, GI, renal and other studies.	Unit IV (12 hrs)	23		8	15
5	Provide knowledge on different aspects of toxicokinetics in drug discovery and development process and alternative methods of animal toxicity.	Unit V (10 hrs)	20			20
Total Marks of Assessment			105	15	15	75

PHA-MPL202T: PHARMACOLOGICAL AND TOXICOLOGICAL SCREENING METHODS II

THEORY

52 hrs

 Basic definition and types of toxicology (general, mechanistic, regulatory and descriptive) Regulatory guidelines for conducting toxicity studies OECD, ICH, EPA and Schedule Y, OECD principles of Good laboratory practice (GLP), history, concept and its importance in drug development.
 10 hrs

2. Acute, sub-acute and chronic- oral, dermal and inhalational studies as per OECD guidelines. Acute eye irritation, skin sensitization, dermal irritation & dermal toxicity studies. Test item characterization- importance and methods in regulatory toxicology studies. **10 hrs**

3. Reproductive toxicology studies, male reproductive toxicity studies, female reproductive studies (segment I and segment III), Teratogenecity studies (segment II), genotoxicity studies (Ames Test, *in vitro* and *in vivo* Micronucleus and Chromosomal aberrations studies), *in vivo* carcinogenicity studies. **10 hrs**

4. IND enabling studies (IND studies) - Definition of IND, the importance of IND, industry perspective, list of studies needed for IND submission. Safety pharmacology studies- origin, concepts, and importance of safety pharmacology. Tier 1- CVS, CNS, and respiratory safety pharmacology, hERG assay. Tier 2- GI, renal and other studies.
12 hrs

 Toxicokinetics - Toxicokinetic evaluation in preclinical studies, saturation kinetics Importance and applications of toxicokinetic studies. Alternative methods to animal toxicity testing.
 10 hrs

REFERENCES

- 1. Handbook on GLP, Quality practices for regulated non-clinical research and development (http://www.who.int/tdr/publications/documents/glphandbook.pdf).
- Schedule Y Guideline: drugs and cosmetics (second amendment) rules, 2005, Ministry of Health and Family Welfare (Department of Health) New Delhi.
- 3. Drugs from discovery to approval by Rick NG.
- 4. Animal Models in Toxicology, 3rd Edition, Lower and Bryan.
- 5. OECD test guidelines.
- 6. Principles of toxicology by Karen E. Stine, Thomas M. Brown.
- Guidance for Industry M3(R2) Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals (http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guida nces/ucm073246.pdf).

SEMESTER II

PHA-MPL203T: PRINCIPLES OF DRUG DISCOVERY

COU	RSE CODE	PHA-MPL20)3T						
COU	RSE TITLE	PRINCIPLES	S OF DRU	G DISCOVE	ERY (Theo	ory)			
	SCOPE/SUMM	IARY	(OBJECTIVES/COURSE OUTCOMES					
The subject imparts basic knowledge of drug discovery process. This information will make the student competent in drug discovery process. Upon completion of the course, the student shall be ab 1. Explain the process of drug discovery and develor including cosmecenticals. 2. Appreciate the importance of the role of generative process. 2. Appreciate the importance of the role of generative process in drug discovery process 3. Explain drug targets in drug discovery process 4. Explain lead seeking methods and lead optimization for the role of computer drug design in drug discovery Course Content and Assessment Plan					pe able to: velopment genomics, ery s zation puter-aided				
		00010				Distributio	on of	marks of	
SI No.	SI No. Course Content			Syllabus (Chapters or Units with hours)	Total Marks of assessment	assessment Sessiona (30 % of to of asses	t al exam otal marks csment)	End Sem ex am (70 % of total marks	
						S1	S2	of assessment)	
1	Understanding the modern dr Students will a of Genomic Bioinformatics discovery. Fur the princip in microarrays, oligonucleotide of transgenic discovery	the fundam ug discovery ilso understand s, Proteomi in ther, students ole involv siRNAs, es and th animals	entals of process. d the role ics and drug will learn ed in antisense he role in drug	Unit I (12 hrs)	18	8		10	
2	Appreciate adv drugs discovery chemistry and l screening, in- assay identification e identification. A structure, appli	vanced techno y such as com high th silico lead o developme tc. for Appreciate th cation of NM	blogies in binatorial broughput discovery, ent and hit lead e protein R and X-	Unit II (10 hrs)	22	7		15	

	ray crystallography in the drug					
	discovery process.					
3	Studentscancomparetraditional and rationaldrugdesign.Students will also learn the structure-based and pharmacophore-based drugdesigns.	Unit III (10 hrs)	22		7	15
4	Students learn the molecular docking and appreciate structure- activity relationship (SAR), and QSAR.	Unit IV (10 hrs)	23		8	15
5	Students will learn advances in QSAR- statistical methods.	Unit V (10 hrs)	24			20
	Total Marks of Assessment			15	15	75

PHA-MPL203T: PRINCIPLES OF DRUG DISCOVERY

THEORY

1. An overview of modern drug discovery process:

Target identification, target validation, lead identification and lead Optimization. Economics of drug discovery. Target Discovery and Validation-Role of Genomics, Proteomics and Bioinformatics. Role of Nucleic acid microarrays, Protein microarrays, Antisense technologies, siRNAs, antisense oligonucleotides, Zinc finger proteins. Role of transgenic animals in target validation.

2. Lead Identification:

Combinatorial chemistry & high throughput screening, in-silico lead discovery techniques, Assay development for hit identification. Protein structure, Levels of protein structure, Domains, motifs, and folds in protein structure. Computational prediction of protein structure: Threading and homology modeling methods. Application of NMR and X-ray crystallography in protein structure prediction.

3. Rational Drug Design:

Traditional vs rational drug design, Methods followed in traditional drug design, High throughput screening, Concepts of Rational Drug Design, Rational Drug Design Methods: Structure and Pharmacophore based approaches, Virtual Screening techniques: Drug likeness screening, Concept of pharmacophore mapping and pharmacophore based Screening.

10 hrs

10 hrs

52 hrs

12 hrs

Page | 62

4. Molecular docking:

Rigid docking, flexible docking, manual docking; Docking based screening. de Novo drug design. Quantitative analysis of Structure Activity Relationship, History and development of QSAR, SAR versus QSAR, Physicochemical parameters, Hansch analysis, Free-Wilson analysis and relationship between them.

5. QSAR Statistical methods

10 hrs

Regression analysis, partial least square analysis (PLS) and other multivariate statistical methods. 3D-QSAR approaches like COMFA and COMSIA, Prodrug design-Basic concept, Prodrugs to improve patient acceptability, Drug solubility, Drug absorption and distribution, site specific drug delivery and sustained drug action. Rationale of prodrug design and practical consideration of prodrug design. Basic concepts of cosmeceutical sciences – Herbal cosmeceuticals, Trends and future research in cosmeceuticals.

REFERENCES

- 1. Mouldy Sioud. Target Discovery and Validation Reviews and Protocols: Volume 2 Emerging Molecular Targetsand Treatment Options. 2007 Humana Press Inc.
- 2. Darryl León, Scott Markel. In Silico Technologies in Drug Target Identification and Validation. 2006 by Taylor and Francis Group, LLC.
- Johanna K. DiStefano. Disease Gene Identification. Methods and Protocols. Springer New York Dordrecht Heidelberg London.
- 4. Hugo Kubiny. QSAR: Hansch Analysis and Related Approaches. Methods and Principles in Medicinal Chemistry. Publisher Wiley-VCH.
- 5. Klaus Gubernator, Hans-Joachim Böhm. Structure-Based Ligand Design. Methods and Principles in Medicinal Chemistry. Publisher Wiley-VCH.
- Abby L., Parrill. M., Rami Reddy. Rational Drug Design. Novel Methodology and Practical Applications. ACS Symposium Series; American Chemical Society: Washington, DC, 1999.
- J. Rick Turner. New drug development design, methodology and, analysis. John Wiley & Sons, Inc., New Jersey.

10 hrs

SEMESTER II

PHA-MPL204T: CLINICAL RESEARCH AND PHARMACOVIGILANCE

COU	RSE CODE	PHA- MPL 204T					
COU	RSE TITLE	CLINICAL RESEARCH	AND PHA	RMACOV	/IGILA	NCE (T	heory)
	SCOPE/S	SUMMARY	OBJEC	TIVES/C	COURS	E OUT	COMES
This current clinic will t desig report focus pharm can b teach data devel surve	subject will pro- nt requirement cal research and teach the studer ning, conduct ting of clinical es on glo nacovigilance ir be used to gener the students in in pre-clinical, of opment ar cillance.	for the students in pharmacovigilance. It its on conceptualizing, ing, managing and trials. This subject also obal scenario of different methods that rate safety data. It will developing drug safety clinical phases of drug ad post-marketing	 Upon comp be able to: Explain conduct devices Demon designs Explain involve Excute close-or Explain Detect assessm Perform systems 	the reg ting a strate the the resp d in clinic e safety ut activitie the princ new adve new adve nemt the adve and covigilant	ulatory clinical e type ponsibil cal trials monito es iples of rse dru erse dru	rse, the s requir trial an s of c ities of ring, re pharmad g reaction ng reaction	tudent should ements for nd medical linical trial key players porting and covigilance ons and their on reporting ation in
		Course Content a	nd Assessme	ent Plan			
Sl No.	C	ourse Content	Syllabus (Chapters or Units with hours)	Total Marks of assessmen t	Distrib assessn Session (30 % d mark assess S1	ution of nent al exam of total (ss of ment) S2	marks of End Sem exam (70 % of total marks of assessment)
1	The learn the origi GCP guideli institutional re ethical guide research and Schedule consent proces	students will n and principles of ICH- nes, functioning of an eview board, explain the elines for biomedical human participants, Y and informed 55.	Unit I (10 hrs)	17	7		10
2	The students v and design trials, response personnel and research organ	vill understand the types gns of clinical ibilities of clinical trial contract ization	Unit II (10 hrs)	23	8		15

3	The students will learn the guidelines for preparation of clinical trial protocol, investigator brochure, case report forms, clinical study report, clinical trial and safety monitoring, and examine the severity and seriousness assessment of ADRs.	Unit III (10 hrs)	22		7	15
4	The students will know the aspects of pharmacovigilance program and evaluation of medication safety.	Unit IV (12 hrs)	20		8	12
5	The students will understand aspects of pharmaco-epidemiology, pharmaco- economics and safety pharmacology including medical devices.	Unit V (10 hrs)	20		-	20
Total Marks of Assessment			105	15	15	75

PHA-MPL204T: CLINICAL RESEARCH AND PHARMACOVIGILANCE

THEORY

1. Regulatory Perspectives of Clinical Trials:

Origin and Principles of International Conference on Harmonization (ICH) - Good Clinical Practice (ICH-GCP) guidelines. Ethics Committee: Institutional Review Board, Ethical Guidelines for Biomedical Research and Human Participant-Schedule Y, ICMR, Informed Consent Process: Structure and content of an Informed Consent Process. Ethical principles governing informed consent process.

2. Clinical Trials:

Types and Design, Experimental Study- RCT and Non RCT, Observation Study: Cohort, Case-Control, Cross-sectional

Clinical Trial Study Team, Roles and responsibilities of Clinical Trial Personnel: Investigator, Study Coordinator, Sponsor, Contract Research Organization and its management.

3. Clinical Trial Documentation

Guidelines for the preparation of documents. Preparation of protocol, Investigator Brochure, Case Report Forms, Clinical Study Report, Clinical Trial Monitoring-Safety Monitoring in CT, Adverse Drug Reactions: Definition and types. Detection and reporting methods. Severity and seriousness assessment. Predictability and preventability assessment, Management of adverse drug reactions; Terminologies of ADR.

10 hrs

10 hrs

0 h.ma

52 hrs

10 hrs

4. **Basic aspects, terminologies and establishment of pharmacovigilance** 12 hrs History and progress of pharmacovigilance, Significance of safety monitoring, Pharmacovigilance in India and international aspects, WHO international drug monitoring programme, WHO and Regulatory terminologies of ADR, evaluation of medication safety, Establishing pharmacovigilance centres in Hospitals, Industry and National programmes related to pharmacovigilance. Roles and responsibilities in Pharmacovigilance Methods, ADR reporting and tools used in Pharmacovigilance.

International classification of diseases, International Nonproprietary names for drugs, Passive and Active surveillance, Comparative observational studies, targeted clinical investigations and Vaccine safety surveillance. Spontaneous reporting system and Reporting to regulatory authorities, Guidelines for ADRs reporting. Argus, Aris G Pharmacovigilance, VigiFlow, Statistical methods for evaluating medication safety data. Introduction to medical devicesregulations governing development and use of medical devices, Medical devices safety and performance.

5. Pharmacoepidemiology, Pharmacoeconomics, safety pharmacology. 10 hrs

REFERENCES

- 1. Central Drugs Standard Control Organization- Good Clinical Practices, Guidelines for Clinical Trials on Pharmaceutical Products in India. New Delhi: Ministry of Health; 2001.
- International Conference on Harmonization of Technical requirements for registration of Pharmaceuticals for human use. ICH Harmonized Tripartite Guideline. Guideline for Good Clinical Practice.E6; May 1996.
- Ethical Guidelines for Biomedical Research on Human Subjects 2000. Indian Council of Medical Research, New Delhi.
- Textbook of Clinical Trials edited by David Machin, Simon Day and Sylvan Green, March 2005, John Wiley and Sons.
- Clinical Data Management edited by RK Rondels, SA Varley, CF Webbs. Second Edition, Jan 2000, Wiley Publications.
- 6. Handbook of clinical Research. Julia Lloyd and Ann Raven Ed. Churchill Livingstone.
- 7. Principles of Clinical Research edited by Giovanna di Ignazio, Di Giovanna and Haynes.

SEMESTER II

PHA-MPL205P: PHARMACOLOGY PRACTICAL II

COURSE CODE PHA-MPL 205P									
COURSE TITLE PHARMACOLOGY PRACTICAL – II									
SCOPE/SUMMARY			OBJECTIVES/COURSE OUTCOMES						
Thi skil dru in t Thi in-s rela gui stud	is subject is des lls on preclinica gs and recent en he drug discover is subject also h silico drug d ationships of delines for pro- dies.	igned to gain practical l testing procedures of xperimental techniques ry and development. elps the students learn lesign, dose-response drugs, international eclinical and clinical	 Upon completion of this course, the student should be able to: Demonstrate, analyze, and compare doseresponse relationship of drugs and quantification of responses of receptor ligands. Understand and apply international guidelines to evaluate drug toxicities and its report. Plan and design in-silico drug candidates for a target protein and critically analyze its druggability. 						
		Course Content	t and Assessme	nt Plan					
Sl No.	Cou	rse Content	Syllabus (Chapters or Experiments with hours)	Total Marks of assessmen t	Distribution asses Sessional exam (25 % of total marks of assessment) S1	a of marks of sment End Sem exam (75 %g of total marks of assessment)			
1	Experiment, analyse dose- ligands usin preparations effects, and concentration ligand by concentration using various b	demonstrate and response of receptor ng in-vitro tissue and quantify their estimate the of a given receptor- omparing it with the standard drug solution bioassays.	Experiments 1 to 10 (90 hrs)	75	17	58			
2	Learn and international g guidelines fo animals and a design and design pro studies based Analyze and reactions to dru various ADR r	understand various guidelines like OECD r toxicity testing in pply the knowledge to toxicity studies tocol for clinical on GCP guidelines. d compare adverse ags in patients and learn reporting methods.	Experiments 11 to 16 and 21 (48 hrs)	39	9	30			

3	Understand and demonstrate in-silico drug design using docking tools, pharmacophore-based screening and evaluate the data using QSAR studies.	Experiments 17 to 20 (18 hrs)	16	4	12
Total Marks of Assessment			130	30	100

PHA-MPL205P: PHARMACOLOGY PRACTICAL II

- 1. To record the DRC of agonist using suitable isolated tissue preparation.
- 2. To study the effects of antagonist/potentiating agents on DRC of agonist using suitable isolated tissue preparation.
- 3. To determine the strength of unknown sample by matching bioassay using suitable tissue preparation.
- 4. To determine the strength of unknown sample by interpolation bioassay using suitable tissue preparation
- 5. To determine the strength of unknown sample by bracketing bioassay using suitable tissue preparation
- 6. To determine the strength of unknown sample by multiple point bioassay using suitable tissue preparation.
- 7. Estimation of PA_2 values of various antagonists using suitable isolated tissue preparations.
- 8. To study the effects of various drugs on isolated heart preparations
- 9. Recording of rat BP, heart rate.
- 10. Recording of rat ECG
- 11. Drug absorption studies by averted chick ileum preparation.
- 12. Acute oral toxicity studies as per OECD guidelines.
- 13. Acute dermal toxicity studies as per OECD guidelines.
- 14. Repeated dose toxicity studies- Serum biochemical, haematological, urine analysis, functional observation tests and histological studies.
- 15. Drug mutagenicity study using mouse bone-marrow chromosomal aberration test.
- 16. Protocol design for a clinical trial. (3 Nos.)
- 17. Design of ADR monitoring protocol.
- 18. In-silico docking studies. (2 Nos.)
- 19. In-silico pharmacophore-based screening.
- 20. In-silico QSAR studies.
- 21. ADR reporting

REFERENCES

- 1. Fundamentals of experimental Pharmacology by M.N. Ghosh.
- 2. Hand book of Experimental Pharmacology-S.K. Kulkarni.
- 3. Text book of in-vitro practical Pharmacology by Ian Kitchen.
- 4. Bioassay Techniques for Drug Development by Atta-ur-Rahman, Iqbal Choudhary and William Thomsen.
- 5. Applied Biopharmaceutics and Pharmacokinetics by Leon Shargel and Andrew B.C. Yu.
- 6. Handbook of Essential Pharmacokinetics, Pharmacodynamics and Drug Metabolism for Industrial Scientists.

MPHARM – PHARMACOLOGY (MPL)

SEMESTER II

PHA-MPL206S: SEMINAR IN PHARMACOLOGY

COURS	SE CODE	PHA- MPL 20)6S							
COURSE TITLE SEMINAR IN PHARMACOLOGY										
-	SCOPE/	SUMMARY		OBJECTIV	E/COURSE	OUTCOMES				
The s enviror the stud openne academ field of	ubject is ment where dents with ss to fortif nic writing s Pharmacolo	designed to c teachers provid a critical ey y the presentat skills of studen ogy.	create an U de and tion and ts in the	 Upon completion able to: 1. Develop skill information, pharmacology 2. Learn to org concepts usin 3. Acquire compresentation s 4. Effectively questions rais scrutiny. 5. Develop a seminar presse 6. Cultivate a se through self a 	of the course, and defend y ganize compl ganize compl ganize compl ag audio-visual munication and skills. respond sed by peers ar write-up on entation. ense of upgrad and continuous	the student shall be organize, deliver a given topic in lex pharmacology aids. d to the nd stand scientific the subject of ation of knowledge s learning				
		Course	e Content a	and Assessment P	Plan	1				
Sl No.	(Course Content		Hours	Total Marks of assessment	End Sem exam				
1	The stude develop sk deliver inf given topio	nts should be fills to gather, o formation, and o to in pharmacolo	able to organize, defend a ogy.	2 hours/week	100	No end-semester examination. Only continuous mode.				

MPHARM – PHARMACOLOGY (MPL)

SEMESTER III

PHA-MRM301T: RESEARCH METHODOLOGY AND BIOSTATISTICS

COUR	RSE CODE PHA-MRM301T						
COUR	SE TITLE RESEARCH METH	ODOLOGY A	ND BIOST	ATISTIC	CS (Theory	<i>y</i>)	
	SCOPE/SUMMARY	OBJ	ECTIVES/	COURS	E OUTCO	OMES	
Sect EnsertimentationSect EnsertimentationThis subject is designed to understand the advanced knowledge for research methodology, ethics in research, medical research, design, conduct and interpretation of results. This subject deals with principles of statistics and their applications in biostatistics involving parametric tests, non-parametric tests, correlation, regression, probability theory and statistical hypotheses.Upon completion of the course, the student s be able to 1. Know the various components of research design and methodology.2. Appreciate advanced statistical technique solving the research problems.							
	Course Cont	tent and Assess	sment Plan	Distri	bution of n	narks of	
Sl No.	Course Contents	Syllabus (Chapters or Units with hours)	Total Marks of assessment	assessment Sessional exam (80 % of total marks of assessment) exa		End Sem exam	
				S1	<u>S2</u>		
1	Research Methodology and study design.	Unit I (10 hrs)	20	20		-	
2	Study the statistical principles and their application in biostatistics. Besides, learning various techniques of biostatistics to interpret the study outcomes.	Unit II (12 hrs)	20	20		_	
3	Learn the CPCSEA guidelines, records and SOPs related to handling and care of experimental animals.	Unit III (10 hrs)	10		10	-	
4	Student will learn the history, principles and concepts of medical research.	Unit IV (10 hrs)	20		20	-	
5	Learn history, basic principles for all medical research and additional principles for medical research combined with medical care.	Unit V (10 hrs)	10		10	-	
	Total Marks	of Assessment	80	40	40	-	

PHA-MRM301T: RESEARCH METHODOLOGY AND BIOSTATISTICS

THEORY

52 hrs

UNIT – I

General Research Methodology: Research objectives, requirements, practical difficulties, review of literature, study design, types of studies, strategies to eliminate errors/bias, controls, randomization, crossover design, placebo, blinding techniques.

UNIT – II

Biostatistics: Definition, application, sample size, importance of sample size, factors influencing sample size, dropouts, statistical tests of significance, null hypothesis, P values, degree of freedom, interpretation of P values. Type of significance tests, parametric tests (students "t" test, ANOVA, Correlation coefficient, regression), non-parametric tests (Wilcoxon rank tests, analysis of variance, correlation, chi square test),

$\mathbf{UNIT}-\mathbf{III}$

CPCSEA guidelines for laboratory animal facility: Goals, veterinary care, quarantine, surveillance, diagnosis, treatment and control of disease, personal hygiene, location of animal facilities and laboratories, anesthesia, euthanasia, physical facilities, environment, animal husbandry, record keeping, SOPs, personnel and training, transport of lab animals.

$\mathbf{UNIT} - \mathbf{IV}$

Medical Research: History, values in medical ethics, autonomy, beneficence, nonmaleficence, double effect, conflicts between autonomy and beneficence/non-maleficence, euthanasia, informed consent, confidentiality, criticisms of orthodox medical ethics, importance of communication, control resolution guidelines, ethics committees, cultural concerns, truth telling, online business practices, conflicts of interest, referral, vendor relationships, treatment of family members, sexual relationships fatality.

$\mathbf{UNIT}-\mathbf{V}$

Declaration of Helsinki: History, introduction, basic principles for all medical research and additional principles for medical research combined with medical care.

MPHARM – PHARMACOLOGY (MPL)

SEMESTER III

MJC 302P: JOURNAL CLUB IN PHARMACOLOGY

COURS	SE CODE	MJC 302P								
COURS	OURSE TITLE JOURNAL CLUB IN PHARMACOLOGY									
	SCOPE/SU	MMARY	OBJECTIV	ES/COURSE	OUTCOMES					
The su environ publish paper, a would o present of the s	ubject is des ment where str and critically and enhance the ation and tudents.	igned to create an udents present a research nalyse it, that communication, analytical skills	 Upon completion of the course, the student shall be able to: 1.Learn to organize complex research concepts using audio-visual aids. 2. Acquire communication and presentation skills. 3. Effectively respond to the questions raised by peers and stand scientific scrutiny. 4. Cultivate a sense of upgradation of knowledge through colf and continuous logrning. 							
		Course Content	t and Assessment Plan							
Sl. No.	Cour	se Contents	Hours	Total Marks of assessment	End Sem exam					
1	The students develop sk organize, de and defend topic in pharm	should be able to cills to gather, eliver information, a given research macology.	2 hours/week	100	No end-semester examination. Only continuous mode.					

MPHARM – CHOICE BASED INTERDISCIPLINARY COURSES PCE-001E: GENERIC DRUG DEVELOPMENT

(15 hrs)

Introduction to Generic Drug Product Development, API, Analytical Methods Development and Methods Validation for Solid Oral Dosage Forms, Experimental formulation development, Scale-Up, Process Validation, Technology Transfer, Drug stability, QC, QA. Drug product performance in vitro, ANDA Regulatory approval process, BE and drug product assessment in vivo, SUPAC, Outsourcing BA and BE studies to CROs, Legal and legislative hurdles.

REFERENCES

- Handbook of Pharmaceutical Generic Development, (oral dosage form volume 24 of Drug development series), Locum publishing house, USA.
- Generic Drug Product Development-Solid Oral dosage form, Leon Shargel and Isadore Kanfer, Marcel Dekker, USA, ISBN: 0-8247-5460-3.

PCE-002E: PHARMACEUTICAL DISSOLUTION TECHNOLOGY

(15 hrs)

2 hrs
2 hrs
2 hrs
2 hrs
1 hr
1 hr
2 hrs
1 hr
2 hrs

REFERENCES

- Pharmaceutical Dissolution Testing by Umesh V. Banakar; Singapore: CRC Press Taylor & Francis Group.
- Pharmaceutical Dissolution Testing by Jennifer Dressman and Johannes Krämer; Singapore: Taylor & Francis Group.

PCE-003E: PARTICULATE DRUG DELIVERY SYSTEMS

(15 hrs)

Microparticulate drug delivery Systems: Introduction, advantages, disadvantages, types, methods of preparation & characterization, in vitro & in vivo evaluations and applications.

6 hrs

Nanoparticulate drug delivery Systems: Introduction, advantages, disadvantages, types, methods of preparation & characterization, in vitro & in vivo evaluations and applications.

9 hrs

REFERENCES

- 1. Encyclopedia of controlled delivery, Editor- Edith Mathiowitz, Published by Wiley Interscience Publication, John Wiley and Sons, Inc, New York. Chichester/Weinheim
- N.K. Jain, Controlled and Novel Drug Delivery, CBS Publishers & Distributors, New Delhi, First edition 1997 (reprint in 2001)
- 3. S.P.Vyas and R.K.Khar, Controlled Drug Delivery concepts and advances, Vallabh Prakashan, New Delhi, First edition 2002
- 4. Nanoteachnology in Drug Delivery, Melgardt M. De Villers, Pornanong Aramwit and Glen S Kwon, Springer.
- 5. Nanoparticulate Drug Delivery Systems, Deepak Thassu, Michel Delees and Yashwant Pathak, Informa Healthcare, NY, USA.
- Nanoparticulates as Drug Carriers, Vladimir P Torchilin, Imperial College Press, London.

PCE-004E: 3D PRINTING IN PHARMACEUTICAL MANUFACTURING (15 hrs)

Introduction, 3D printing technologies, printing based inkjet systems, Nozzle based deposition systems, Laser based writing systems, 3D printing for customized drug delivery systems, Limitations and challenges.

REFERENCES

- 1. 3D printing in pharmaceutics: A new tool for designing customized drug delivery systems. Goole Jonathan and Amighi Karim, Int. J Pharm. 499 (2016), 376-394.
- 3D fabricated polymer-based drug delivery systems, Simon Moulton and Gordon G Wallace, J of Cont. Rel. 193 (2014), 27-34.
- Fabrication of printed drug delivery systems. Natalja Genina, Ruzica Kolakovic, Mirja Palo, Daniela Fors, Helka Juvonen, Petri Ihalainen, Jouko Peltonen, Niklas Sandler, NIP 29 and Digital Fabrication (2013), 236-238.

PCH-001E: PREPARATIVE SEPARATION TECHNIQUES (15 hrs)

- Column chromatography: Introduction, stationary phase, mobile phase selection, column selection, sample loading techniques, elution technique.
 9 hrs
- Flash chromatography: Principle, advantages, instrumentation, mobile phase selection, column selection, sample loading techniques, elution technique.
 6 hrs

PCH-002E: MOLECULAR MODELLING AND DRUG DESIGN (15 hrs)

1. Molecular Geometry, Molecular mechanics, Quantum mechanics, Molecular dynamics, Pharmcophore, Molecular docking, Library generation and structure-based drug design.

> 12 hrs 3 hrs

2. Database and Software Resources

PCH-003E: HYPHENATED TECHNIQUES

(15 hrs)

Principle and applications of following hyphenated techniques

1. GC-MS	4. EC-MS	7. LC-MS-MS	10. GC-AES
2. LC-MS	5. CE-MS	8. GC-MS-MS	
3. LC-NMR	6. GC-IR	9. GC-NMR	

PCH-004E: CHEMICALS-ENVIRONMENT, HEALTH AND SAFETY

(15 hrs)

Chemical	safety,	Chemical	hazards,	handling	of	chemicals/gases,	storage	of	chemicals,
chemical v	waste di	sposal.							8 hrs
First aid p	rocedure	es							1 hr

tory practice	es:					2 hrs
tection						1 hr
materials:	Regulatory	requirements,	hazards,	handling,	storage,	disposal,
rocedures.						2 hrs
						1 hr
	ory practice tection materials: rocedures.	tory practices: tection materials: Regulatory rocedures.	tory practices: tection materials: Regulatory requirements, rocedures.	tory practices: tection materials: Regulatory requirements, hazards, rocedures.	tory practices: tection materials: Regulatory requirements, hazards, handling, rocedures.	tory practices: tection materials: Regulatory requirements, hazards, handling, storage, rocedures.

PQA-001E: THEORY AND PRACTICE OF ANALYTICAL AND BIOANALYTICAL METHOD DEVELOPMENT AND VALIDATION (15 hrs)

1.	Introduction to the concept of validation.	1 hr
2.	Development of analytical method using UV/PDA spectroscopy,	
	Fluorimetry, HPLC, LC-MS/MS.	4 hrs
3.	Validation of the analytical method as per ICH-Q2(R1).	3 hrs
4.	Development of bioanalytical method using HPLC and LC-MS/MS.	2 hrs
5.	Validation of bioanalytical method as per USFDA guidance.	3 hrs
6.	Introduction to Novel upcoming technologies in bioanalysis	
	like dry matrix spot analysis.	1 hr
7.	Introduction to Analysis of therapeutic proteins and peptides.	1 hr

Evaluation

Formative: Development of validation protocols & problem-based learning.	(30%)
Summative: Open book periodical tests & end semester exam.	(70%)

PQA-002E: GOOD DOCUMENTATION PRACTICES AND E-DOCUMENTATION PRACTICES IN PHARMACEUTICAL INDUSTRY

(15 hrs)

Introduction to GDP and E – documentation	3 hrs
Basic levels of documentation	6 hrs
a. Level -1, Level-2, Level-3 and Level-4 documentation	
Case studies in each level	3 hrs
Open lab and e-documentation concept	3 hrs
	Introduction to GDP and E – documentation Basic levels of documentation a. Level -1, Level-2, Level-3 and Level-4 documentation Case studies in each level Open lab and e-documentation concept

PQA-003E: TROUBLE SHOOTING IN HIGH PERFORMANCE LIQUID

CHROMATOGRAPHY

(15 hrs)

1.	Introduction	on t	o HPLO	C	modu	iles	and	l so	our	ce o	of errors/malfunction in HPLC	2	5 hrs
-	~				_								

- 2. Startup preliminary checks for trouble shooting6 hrs
- 3. Trouble shooting in HPLC module wise including demonstration 4 hrs

PQA-004E: PROFESSIONAL DEVELOPMENT

(15 hrs)

- 1. Introduction to Professional Career Development
- 2. Introduction to Career Planning: Self Assessment
- 3. Identifying Your Professional Talents
- 4. Introduction to Career Planning: Career Exploration
- 5. Developing Your Professional Resume
- 6. Enhancing Your Professional Resume
- 7. Preparing Your Career and Internship Cover Letters
- 8. Professional Communications
- 9. Preparing for Your Employment an Internship Interviews
- 10. Conducting Your Employment and Internship Interviews
- 11. Introduction to the Career Fair Search Process
- 12. Exploring Internship Options within Your Profession
- 13. Networking Search Strategies
- 14. Developing Your Professional Career Portfolio
- 15. Influencing Your Networking Partners
- 16. Essential practical skills and problem solving
- 17. communication of scientific information
- 18. IT skills.

Assessments:

- assignments
- case studies
- portfolios
- presentations

PQA-005E: STABILITY TESTING OF DRUGS AND BIOLOGICALS

(15 hrs)

- 1. Introduction to drug stability and its importance.
- 2. Stability testing of drug substances and drug products as ICH Q1 series guidelines 11 hrs
- 3. Stability testing of biotechnological/biological products as per ICH Q5C guidelines. 2 hrs

PQA-006E: USFDA DRUG REGULATORY AFFAIRS

(15 hrs)

- 1. Process of new drug development.
- 2. Contents of IND, NDA, CTD and eCTD, ANDA
- 3. SMF and DMF
- 4. Post marketing regulatory requirements.

PQA-007E: REST OF THE WORLD DRUG REGULATIONS

(15 hrs)

Legislation and regulations for import, manufacture, distribution and sale of drugs and pharmaceuticals in:

- 1. Brazil
- 2. ASEAN countries
- 3. CIS countries
- 4. GCC Countries.

PQA-008E: EVALUATION OF MEDICAL DEVICES

(15 hrs)

A. Biological evaluation of medical devices

Scope, General principles applying to biological evaluation of medical devices, categorization of medical devices, testing, selection of biological evaluation tests, Assurance of test methods

B. Clinical evaluation of Medical devices 5 hrsImportance, scope, clinical evaluation in brief

10 hrs

PBT-001E: CLEAN ROOM CONCEPTS

(15 hrs)

Unit 1. Fundamental aspects of microbiology

Morphology, Microscopy, Growth and Controlling Growth of Microorganisms.

Unit 2. Clean Room aspects

Clean Room concepts, layout, facilities, HEPA and ULPA Filter, biosafety cabinets and various classes, biosafety levels, personnel controls.

Unit 3. Microbial monitoring, detection and enumeration of microorganisms 6 hrs Monitoring techniques, air samples, microbiological assessment of liquids, solids and semisolids, disposal of cultures.

REFERENCES

- Cleanroom Microbiology for the Non-microbiology by David M. Carlberg, Second Edition CRC press, 2005.
- Biopharmaceutical, Biochemistry and Biotechnology, Second Edition, Gary Walsh, Wiley Publishers, 2003.

PBT-002E: BIOSIMILARS

(15 hrs)

Unit -I Biosimilars- Introduction

Definitions, Generics and Branded drugs, biosimilars, introduction to biologics, differences between biosimilars and generics, manufacturing process and technical challenges associated with production of biosimilar molecules, status of biosimilars. The role of patents in the drug industry and protein-based biopharmaceuticals.

Unit –II Guidelines on Similar Biologic: Regulatory Requirements for Registration and Marketing Authorization in India 8 h

Principles for Development of Similar Biologics, Competent authorities, Selection of reference biologics, Quality consideration of similar biologics, Quality comparability study, Data requirement for preclinical study, clinical application and market authorisation, Post market data for similar biologics.

REFERENCES

- 1. Proposed guidelines for similar biologics in India, CDSCO.
- 2. Biosimilars and Interchangeable Biologics: Strategic Elements By Sarfaraz K. Niazi
- 3. Guidelines from Indian regulatory bodies such as CDSCO, DBT etc. issued time to time.
- 4. Relevant journals and periodicals.

7 hrs

3 hrs

6 hrs

PBT-003E: PRINCIPLES OF GENE CLONING

(15 hrs)

Unit I 3 hrs The aims of Gene Cloning: Techniques of gene manipulation, Outline of gene cloning. Unit II 6 hrs Gene Cloning: Gene cloning procedure, tools required for gene cloning, cloning strategy, techniques for selection of clones, preservation of clones. **Unit III** 6 hrs **Applications of Gene Cloning:** In production of therapeutic proteins, diagnostic proteins, transgenic animals and plants. REFERENCES 1. Molecular biotechnology, Bernard R. Glick, Jack J. Pasternak, Cheryl L. Patten,

2. Biotechnology: The Biological Principles, M.D. Trevan, S. Boffey, K.H. Goulding and P. Stanbury. 1998, Tata McGraw Hill Edition.

PBT-004E: TISSUE ENGINEERING

(15 hrs)

Introduction to Tissue Engineering: Animal cell culture fundamentals, concept and need of tissue engineering, historical prospective, current status, industry challenges

Unit II

Biomaterials for Tissue Engineering: Overview, features of scaffold and biomaterials, types of biomaterials, nanofiberous material as biomaterial.

Unit III

Applications of Tissue Engineering: in Bone tissue regeneration, vascular tissue engineering, skin regeneration, cardiac tissue engineering and neural tissue engineering.

REFERENCES

- 1. Principles of Tissue Engineering, 4th Edition, Robert Vanza, Robert Langer, Joseph Vacanti. 2014. Academic Press.
- 2. Exploring Nanotechnology in Healthcare, Edited by N. Udupa, 2013, Manipal University Press.

Unit I

2010, ASM Press.

Page | 81

5 hrs

5 hrs

PPR-001E: RETAIL PHARMACY PRACTICE

(15 hrs)

- Retail Pharmacy Management: Site selection, acquisition of premises for a retail pharmacy, layout of drug store, Legal aspects of retail pharmacy (includes Schedule N requirement), role of retail pharmacist and Code of ethics for practicing pharmacists.
- Purchase and inventory control, stocking, sale promotion, maintenance of records, economics and management
 5 hrs
- 3. Communication skills2 hrs4. Medication therapy management2 hrs5. Patient counselling2 hrs

REFERENCES

I. Introduction

- Philip P. Gerbino. Remington: The Science and Practice of Pharmacy. Philadelphia, PA. Lippincott Williams & Wilkins. (latest edition)
- 2. Revikumar KG,Miglani BD. A Text Book of Pharmacy Practice. Career Publications (latest edition)
- G Parthasarathi, Karin Nyfort Hansen, Milep C Nahata. A Textbook of Clinical Pharmacy Practice Essential Concept and Skill. Oriental Longman Private Limited (latest edition)
- 4. Ashley WE, Justin J. Community and clinical pharmacy services: A step-by-step approach. The McGraw-Hill Companies, Inc, USA

PPR-002E: FUNDAMENTALS OF MEDICAL WRITING

(15 hrs)

	\triangleright	Brief overview of scientific writing		
	\triangleright	Scope and importance		
	\triangleright	Different types and areas of writing		
	\triangleright	Career and opportunities		
2. 1	Basic I	Need To Be A Good	4	hrs
	\triangleright	Language and Style in Medical Writing		
	\triangleright	Literature search		
		-Data bases (Medline, PubMed, Cochrane)		

Page | 82

- Searching principles (using MeSH, Pub Med)
- Developing searching strategy by PICO
- Cortical Analysis Scientific Paper
- > Ethics in Publication (Plagiarism, Copy Rights etc)
- ➢ Reference Writing
 - Different bibliographic styles
 - -Citation databases
 - -Software used in reference writing

3. Different Types of Medical Writing

- Structured abstract writing
- Report writing and sub-types
- Medication leaflets/pills
- Clinical research form
- Informed consent
- Protocol writing
- Case record form
- > PSUR
- > News letter

4. MANUSCRIPT WRTING AND PUBLICATION

- ➢ ICMJE guidelines
- ➢ How to prepare structured manuscript (IMRA)
- Presentation of data (tables , figures and algorithms)
- Conflict of interest
- Acknowledgement
- Publication issues

Assignments: Preparation of power point, poster, abstract writing, review article with hand on training in publication issues

REFERENCES

1.Janice R Mathews, Jobin M Bowen and Robert W Mathews .Successful scientific writing-A step by step guide for the biological and medical sciences; 1996

7 hrs

2. Piyush Gupta, Navjeevan Singh. How to write thesis and thesis protocol-A primer for medical, dental & nursing courses; 2014

3. John Kirkman. Good style – Writing for science & Technology; 1994

4. Jennifer peat, Elizabeth Elliot, Louise Bour. Scientific writing-Easy when you know how; 1994.

PPR-003E: SYSTEMATIC REVIEW AND META-ANALYSIS

(15 hrs)

1.	Study designs: Introduction to Case-control studies, Cohort studies, Randomized	
	controlled trials	1 hr
2.	Applied statistics: Descriptive statistics, Hypothesis, Null-hypothesis, type-1 & ty	pe-2
	errors, power, p-value, Confidence intervals, Odds ratio, Relative risk (risk ratio),	Fixed
	effects & Random effects, Concept of homogeneity & heterogeneity and tests for	
	heterogeneity, Various types bias and methods to detect bias, Funnel plot, Effect s	ize &
	effect size indices, Forest plot	3 hrs
3.	Evidence based clinical practice: Definition, importance, levels of evidence.	1 hr
4.	Systematic review and meta-analysis: Definition, types, importance, applications,	
	Meta-analysis groups (Campbell Collaboration, Cochrane Collaboration)	1 hr
5.	Steps involved in conducting Systematic review and Meta-analysis:	5 hrs
	a. Framing the question	
	b. Literature search	
	c. Assessing the quality of studies	
	d. Selection of studies	
	e. Data synthesis & Analysis	
	f.Summarizing the evidence	
	g. Interpretation of the findings	
6.	Introduction to softwares used in meta-analysis: MedCalc, Comprehensive Meta-	
	analysis software, RevMan, Open meta-analysis	1 hr
7.	Writing a meta-analysis protocol, Literature search, Data synthesis & analysis	
	(Assignments)	3 hrs

REFERENCES:

 Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions 4.2.6 [updated September 2006]. In: The Cochrane Library, Issue 4, 2006. Chichester, UK: John Wiley & Sons, Ltd. Borenstein, M, Hedges LV, Higgins JPT, Rothstein HR. Introduction to Meta-Analysis. John Wiley & Sons, Ltd., 2009.

Pre-requisites: Knowledge of Biostatistics & Research Methodology, Web-based literature search

Evaluation: Based on Assignments

PPR-004E: PHARMACOKINETICS DATA ANALYSIS

(Employing WinNonlin)

(15 hrs)

- 1. Introduction to pharmacokinetic parameters: Elimination rate constant (ke), Elimination half-life, Bioavailability & AUC, Volume of distribution, Clearance, Bioequivalence 2 hrs
- 2. Bioavailability studies: In animal & human 2 hrs
- 3. PK parameters for Oral & IV administration: Calculation of PK parameters for oral & IV administration by plotting concentration vs time graph (using semi-log graph paper)

		2 hrs
4.	Introduction Phoenix WinNonlin: Data entry and data tools, graphs	2 hrs
5.	Non-compartmental analysis using (NCA) Phoenix WinNonlin: For Oral, IV, IV	
	infusion, Sparse sampling and urinary excretion data	3 hrs
6.	Pharmacokinetic modeling: Compartment modelling, choosing the right compartr	nent
	model, Simulating using PK model	2 hrs
7.	Bioequivalence data analysis: Parallel, Cross-over study data analysis	2 hrs
Rŀ	EFERENCES	
	1. Gibaldi M, Perrier D. Pharmacokinetics. 2 nd edition. Informa Healthcare; 2007	7.
		a

- Rowland M, Tozer TN. Clinical Pharmacokinetics: Concepts & Applications. 4th edition. Lippincott Williams& Wilkins;2011.
- 3. Phoenix WinNonlin examples guide. Pharsight. A Certara Company; 2012
- 4. Phoenix WinNonlin Users guide. Pharsight. A Certara Company; 2012.
- 5. Guidance for Industry: Bioavailability and Bioequivalence Studies Submitted in NDAs or INDs- General Considerations. US FDA. 2014.

Pre-requisites: Knowledge of basic pharmacokinetics.

Evaluation: Based on Assignments.

PHA-001E: CANCER BIOLOGY

(15 hrs)

Objectives/Course Outcomes

This course aims to provide students an extensive understanding about cancer and its effects on the human body. This course will also discuss the historical aspect of cancer research, basic chemotherapeutics and future scope in cancer research. All the topics will be presented in a simplified scientific manner with an emphasis on gaining a broad understanding of the disease.

- Advanced Cell Biology- Structural and functional basis of cell, structure of chromosome and DNA, Cell cycle and its regulation. 3 hrs
- Molecular and genetic basis of cancer- Growth signaling, dysfunction of cell cycle leading to cancer, Oncogene, tumor suppressor gene, Apoptosis
 6 hrs
- Cellular aspect of cancer- History of cancer, six hallmarks of cancer, Types of cancer, Metastasis, Cancer Prevention and Treatment.
 3 hrs
- Current trends in Cancer research- Targets for development of cancer chemotherapeutics, its identification and relevance, Recent advancements in cancer therapy.
 3 hrs

PHA-002E: SCREENING METHODS FOR DRUG DEVELOPMENT (15 hrs)

The course aims at providing the conceptual learning of a few basic pharmacological approaches to elucidate the pharmacological activity of a new chemical entity. The knowledge of screening methods facilitates the understanding of animal models, which closely mimics the human pathology, to screen the promising molecules for developing a new drug.

- 1. Introduction: General Screening techniques
- 2. Screening methods for local anesthetics
- 3. Screening methods for anti-hypertensive drugs
- 4. Screening methods for anti-arrhythmic drugs
- 5. Screening methods for anti-inflammatory drugs
- 6. Screening methods for analgesic drugs
- 7. Screening methods for antipyretic drugs
- 8. Screening methods for anticancer drugs
- 9. Screening methods for antidiabetic drugs

- 10. Screening methods for anti-dyslipidemia drugs
- 11. Screening methods for antiepileptic drugs
- 12. Screening methods for antidepressant drugs
- 13. Screening methods for antianxiety drugs
- 14. Screening methods for antiparkinsonian drugs
- 15. Screening methods for Alzheimer's disease related dementia

PHA-003E: FREE RADICAL BIOLOGY AND MEDICINE (15 hrs)

Objectives

To provide fundamentals which are essential for researchers who wish to pursue problems of human health that involve free radicals, related oxidants, antioxidants, and antioxidant enzymes. Students will be able to understand, interpret, and critically think on issues associated with major causes of health problems.

- 1. Basics of free radicals in biology and medicine
- 2. Concept of oxidative stress in biology and diseases
- 3. Oxidative stress markers
- 4. Radical scavengers: The concept of antioxidants
- 5. Redox signaling and NRF2-ARE signaling mechanisms
- 6. Free radicals in inflammation and immune disorders
- 7. Free radicals in diabetes, obesity and metabolic disorders
- 8. Free radicals in cancer
- 9. Free radicals in cardiovascular diseases
- 10. Free radicals in neurodegenerative disorders
- 11. Free radicals and ageing
- 12. Free radicals in infectious diseases and antimicrobial-resistance
- 13. Free radicals in hepato-biliary diseases
- 14. Antioxidants screening methods: In vitro and in vivo
- 15. Recent advances in antioxidant discovery and development

Study material: Recent journal articles from reputed and Open Access Journals

PHA-004E: REGULATORY TOXICOLOGY IN DRUG DISCOVERY AND DEVELOPMENT (15 hrs)

Objectives

This subject is to project the importance of safety testing in pre-clinical research and harmonized standards that they have to adopt for safety testing procedures.

Introduction: General Principles of Toxicology, Agencies and their guidelines regardingToxicology studies, Concept of Good Laboratory practices.3hrs

Guidelines for safety testing

Pharmacological studies:Safety Pharmacology Studies for Human Pharmaceuticals, QTinterval prolongation study in animals.3 hrs

Toxicity testing: Toxicokinetics: The Assessment of Systemic Exposure in Toxicity Studies,Pharmacokinetics: Guidance for Repeated Dose Tissue Distribution Studies, Acute, subacuteand Chronic toxicity in animals**4 hrs**

Special toxicity studies:Non-clinical Carcinogenicity studies, Genotoxicity studies,Reproductive toxicology, Immunotoxicity, Safety evaluation of Biotechnology- derivedproducts.5 hrs

PCO-001E: NUTRACEUTICALS

(15 hrs)

Scope

Nutraceuticals: The food or part of food with additional health benefits are emerging as major health supplements for prevention, management and some-times cure of various diseases. In the current fast lifestyle, nutraceuticals are encroaching pharma markets not only in the developed but also in the developing countries. Therefore, an additional knowledge in nutraceuticals or health supplements add an edge to the student.

Objectives

The course proposes to offer a comprehensive knowledge on the nutraceuticals and their importance to prepare the student for a pursuit in the health food sector.

1.	Introduction to nutraceuticals: Overview, classification, benefits of	3 hrs
	nutraceuticals, functional foods	

2.	In organic supplements and vitamins	1 hr
3.	Probiotics, prebiotics and digestive enzymes	1 hr
4.	Dietary supplements and fibres	1 hr
5.	Antioxidants and PUFAs	2 hrs

- 6. Herbs as health foods: Poly phenols and flavonoids (*Ginkgo biloba*, 5 hrs Tea, Citrus fruits, Grape, Soy); Carotene and fatty acids: (Curcuma, Tomato, Flax seed, Olive oil)
 7. Current market scenario of nutraceuticals 1 hr
- 6. Regulatory requirements for nutraceuticals 1 hr

REFERENCES

- 1. Biren Shah and A.K. Seth. Text Book of Pharmacognosy and Phytochemistry, Ed1, Elsevier Health Sciences, Gurgaon, Haryana, 2010. Pp 471-83
- 2. S.S. Agrawal and M. Paridhavi. Herbal Drug Technology, Ed2, Universities Press, Hyderabad, Telangana, 2012. Pp 710-21
- Alberta N.A. Aryee and Joyce Irene Boye, Current and Emerging Trends in the Formulation and Manufacture of Nutraceuticals and Functional Food products, In, Nutraceutical and Functional Food Processing Technology Edt. Joyce Irene Boye, Ed.1. Wiley Blackwell, West Sussex UK, 2015. Pp 01-52
- 4. Rorimi E. Aluko, Functional Foods and Nutraceuticals Springer, New York, USA, 2012.
- 5. C.K Kokate, A.P. Purohot and S.B. Gokhale, Pharmacognosy, Vol 1 and 2, Ed. 46, Nirali Prakashan, Pune, 2010. Pp 6.01-6.16

PCO-002E: EXTRACTION, SEPARATION AND PURIFICATION OF <u>PHYTOCONSTITUENTS</u>

(15 hrs)

Scope

Herbal drugs are emerging as major source of biomedicines worldwide. Secondary metabolites or phytoconstituents are responsible for medicinal attributes of a plant. Extraction, separation, and purification of these secondary metabolite is an area of interest for researchers. Therefore, this subject will provide an insight on the topic so as to enable the students to carry their research on natural products effectively.

Objectives

To impart stronger scientific base in the area of extraction, isolation and purification principles and methodologies of crude drugs.

- 1. Introduction to plant metabolites.
- Extraction techniques: Principle, merits & demerits, applications of 5 hrs maceration, decoction, infusion, percolation, soxhlet extraction, supercritical fluid extraction, microwave-assisted extraction, ultrasound extraction (sonication), advanced phytonics method of extraction, expression and enfleurage method.
- 3. Phytochemical screening of natural products 2 hrs
- Separation and purification of phytoconstituents: Fractional 7 hrs 4. fractional liberation. distillation, sublimation. fractional crystallization, gel filtration, counter current extraction and chromatographic techniques like Paper Chromatography, TLC, HPLC. HPTLC. column chromatography, gas-liquid chromatography, droplet counter current chromatographyand electrochromatography (Electrophoresis).

REFERENCES

- Evans W. C., Trease G. E., Trease and Evan's Pharmacognosy. W.B. Saunders, 2002. 16th Ed.
- Jean Bruneton, Caroline K. Hatton, Pharmacognosy, Phytochemistry, Medicinal Plants. Lavoisier, 1999
- 3. Kokate C.K., Gokhale S.B. and Purohit A.P., Textbook of Pharmacognosy, Nirali Prakashan, Pune, 2008
- 4. Mukherjee Pulok K., Quality Control of Herbal Drugs: An Approach to Evaluation of Botanicals. Business Horizons, 2002.

PCO-003E: NANOPHYTOPHARMACEUTICALS

(15 hrs)

Scope

Nanotechnology is a cutting-edge technology that provides optimal effectiveness in low doses. The course addresses and provides an overview of phytopharmaceuticals in nano size for better therapeutic benefits along with toxicity. Students will be able to understand the benefits of nano-phytopharmaceuticals.

1 hr

Objectives

To study the effectiveness in low doses and enhancement of bioavailability of phytopharmaceuticals for better therapeutic values

1.	Definition and history of nanotechnology	1 hr
2.	Properties – optical, electrical and magnetic properties of	2 hrs
	nanomaterials	
3.	Preparation techniques – Polymeric nanoparticles, liposomes, micelles	6 hrs
	and herbal nanoparticles	
4.	Toxicity studies	2 hrs
5.	Applications of phytopharmaceuticals, nanophytopharmaceuticals in	4 hrs
	the treatment of certain diseases	

REFERENCES

- Nano: The Essentials: Understanding Nanoscience and Nanotecnology, T. Pradeep, Tata McGraw-Hill Publishing Company Limited, New Delhi, 2008.
- Nanocrystals: Synthesis, Properties and Applications, C. N. R. Rao, P. J. Thomas and G. U. Kulkarni, Springer (2007)
- Nanostructures & Nanomaterials: Synthesis, Properties & Applications, Guozhong Cao, Imperial College Press (2004).
- 4. Nanoparticles as Drug carriers, Vladimir P Torchilin, Imperial College Press, USA, 2006
- Multifunctional Pharmaceutical Nanocarriers, Vladimir Torchilin, Springer Publishing, New York, NY, 2008.

PCO-004E: HERBAL MONOGRAPHS

(15 hrs)

Scope

A monographs is written document intended to promote information exchange and international harmonised standards for the quality control and use of herbal medicines. It contains scientific information on selected medicinal plants that serves as a summary for quality assurance, clinical applications and dosage forms. The proposed course is designed to study and understand herbal monographs

Objectives

To impart knowledge on systematic study of herbal drugs with reference its identity, quality and purity

- Introduction to monographs, purpose and content of the monographs, 3 hrs use of the monographs
- Systematic study of the following important plants for their 12 hrs monographs;

Leaf: Vasaka (*Adhatoda zeylanica*) Root: Shatavari (*Asparagus racemosus*) Rhizome:Rasna (*Alpinia galanga*) Bark: Cinchona (*Cinchona officinalis*) Fruit: Pepper (*Piper nigrum*) Entire herb: Kalmegh (*Andrographis paniculata*).

REFERENCES

- WHO monographs on selected medicinal plants. Geneva: WHO. Vol. 1. 1999, Vol. 2. 2002, – Vol. 3: 2004, – Vol. 4. 2005.
- Quality Standards of Indian Medicinal Plants Indian Council of Medical Research, New Delhi.
- Indian Herbal Pharmacopoeia A Joint Publication of RRL, Jammu and IDMA, Mumbai.

PRM-001E: RETAIL BUSINESS MANAGEMENT

(15 hrs)

Scope

This course is formulated to impart knowledge on retail management. It also provides an overview about the nitty-gritties of managing a pharmacy store and an overview of Online Pharmacies.

1. Introduction to Retail Management	3 hrs
2. Strategies in Retailing	3 hrs
3. Retail Marketing in rural areas	3 hrs
4. Pharmacy Store Management	4 hrs
5. Online Pharmacy Retailing	2 hrs

REFERENCES

- 1. Retail Management by Barry Berman. Person Education 11th Edition.
- 2. Retail Management by Chetan Bajaj. Oxford 2nd Edition.
- 3. Retail Management: Text and Cases by UC Mathur. IK International Publishing House Pvt. Ltd.

PRM-002E: INTELLECTUAL PROPERTY MANAGEMENT

(15 hrs)

Scope

This course deals with Intellectual Property Rights with special emphasis on Patents.

1. Basic Concepts of Intellectual Property Rights	3 hrs
2. Patent Administration in India and Patent Filing	3 hrs
3. Revocation of Patents and Patent Infringement Cases	3 hrs
4. Data Protection and Exclusivity	3 hrs
5. Patent as a business tool	3 hrs

REFERENCES

1. Basic Concepts of Intellectual Property Rights by Manthan D Janodia. Manipal University Press, 2015.

2. Intellectual Property Rights by SRS Rosedar. Lexis Nexis 2016.

3. Intellectual Property Rights in India by VK Ahuja. Lexis Nexis, 2015.

4. Law relating to Intellectual Property by BL Wadehra. Universal Law Publishing, 2016.

PRM-003E: GENERAL MANAGEMENT PRINCIPLES

(15 hrs)

Scope

This course is designed to facilitate students to inculcate managerial skills. It includes major concepts of management.

1. Introduction to management concepts	3 hrs
2. Decision Making	3 hrs
3. Leadership and Motivation	4 hrs
4. Conflict Management	3 hrs
5. Ethical Issues related to Management	2 hrs

REFERENCES

1. Organisational Behaviour by Stephen P. Robbins, Prentice – Hall, India

2. Management, A global Perspective by Heinz, Weihrich and Harold Koontz. Mc Graw Hill publishing company.

3. Management, tasks, responsibilities and practices by Drucker. Peter. F., Alfied Publisher Pvt. Ltd.

4. Principles and Practice of Management by L M Prasad, Sultan Chand & Sons.

PRM-004E: ENTREPRENEURSHIP DEVELOPMENT

(15 hrs)

Scope

This course is designed to impart knowledge and skills on entrepreneurship development.

1. Entrepreneur and Entrepreneurship	3 hrs
2. Entrepreneurial Development	3 hrs
3. Launching and Organizing an enterprise	3 hrs
4. Cost and Pricing	3 hrs
5. Project proposal development for start-up	3 hrs

REFERENCES

1. Hisrich, R.D. and Peters, M.P. (1995): Entrepreneurship – Starting, Developing and Managing a New Enterprise, Richard D., Inwin, INC, USA.

2. Meredith, G.G. etal (1982): Practice of Entrepreneurship, ILO, Geneva.

3. Entrepreneurship Management by Vasant Desai. Himalaya Publishing House, 2011.

MPHARM – CHOICE BASED MULTIDISCIPLINARY COURSE

- MU-001E: Certificate Course in Bioinformatics
- MU-002E: Project Management
- MU-003E: Certificate Course in Bioethics
- MU-004E: Academic Research and Writing
- MU-005E: Certificate Course in Biosecurity

(As prescribed from time to time)